

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR (CARE)

England & Wales · Charity number 802862

## Details

---

**Status** Registered

**Legal form** Other

**Registered** 1990-03-05

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** Addenbrookes Hospital Nhs Trust  
Addenbrookes Hospital  
Hills Road  
Cambridge  
CB2 0QQ

**Phone** 01223217457

**Email** [cuh.rcru@nhs.net](mailto:cuh.rcru@nhs.net)

**Website** [www.cambridge-arthritis.org.uk](http://www.cambridge-arthritis.org.uk)

## Activities

---

**Objects:** THE RELIEF OF PERSONS WHO ARE SUFFERING FROM RHEUMATOID ARTHRITIS AND RELATED DISEASES AND TO PROMOTE AND ADVANCE MEDICAL RESEARCH AND EDUCATION CONCERNING SUCH DISORDERS PROVIDED THAT THE USEFUL RESULTS OF SUCH RESEARCH SHALL BE PUBLISHED.

**Activities:** Supporting scientific research into rheumatological conditions, taking various forms including laboratory-based investigation of the basic mechanisms underlying diseases of the musculoskeletal system, clinical research to investigate the features and natural history of these disorders, and to improve their management and therapy, mainly in the context of randomised clinical trials.

## Classification

---

- **How:** Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

## Geography

- Cambridgeshire

## Finances

| Period end | Income   | Expenditure | Assets | Employees |
|------------|----------|-------------|--------|-----------|
| 2025-03-31 | £77,841  | £235,902    | -      | -         |
| 2024-03-31 | £117,843 | £273,256    | -      | -         |
| 2023-03-31 | £294,923 | £192,587    | -      | -         |
| 2022-03-31 | £112,922 | £196,896    | -      | -         |
| 2021-03-31 | £76,517  | £210,478    | -      | -         |

## Trustees

| Name                               | Role | Appointed  |
|------------------------------------|------|------------|
| Dr FRANCES CLARE HALL              |      |            |
| Dr NICHOLAS GS SHENKER             |      |            |
| Fidelma Gordon                     |      | 2025-10-24 |
| His Honour Christopher Hodson      |      | 2022-10-24 |
| PROFESSOR JOHN STANLEY HILL GASTON |      |            |
| Professor Andrew W McCaskie        |      | 2015-09-29 |
| Sarah Ramsay                       |      | 2022-10-24 |
| Stacey Hartshorn                   |      | 2021-11-22 |

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR (CARE)**

England & Wales - Charity number 802862

---

# Accounts

---

Charity registration number 802862 (England and Wales)

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR  
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## LEGAL AND ADMINISTRATIVE INFORMATION

---

|                             |   |
|-----------------------------|---|
| <b>Trustees</b>             | Professor H Gaston<br>Dr N Shenker<br>Dr F Hall<br>Professor A McCaskie<br>S Hartshorn<br>S Ramsay<br>His Honour Christopher Hodson |
| <b>Charity number</b>       | 802862  |
| <b>Registered office</b>    | Box 194 Unit E6<br>Addenbrookes Hospital<br>Hills Road<br>Cambridge<br>CB2 0QQ  |
| <b>Independent examiner</b> | Ms J Boatfield FCA, DChA<br>Ensors<br>First Floor<br>Victory House<br>Vision Park<br>Histon<br>Cambridge<br>CB24 9ZR                |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## CONTENTS

---

|   | <b>Page</b> |
|---|-------------|
| Trustees' report                        | 1 - 4       |
| Statement of Trustees' responsibilities | 5           |
| Independent examiner's report           | 6           |
| Statement of financial activities       | 7           |
| Balance sheet                           | 8           |
| Notes to the financial statements       | 9 - 17      |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 MARCH 2025

---

The Trustees present their annual report and financial statements for the year ended 31 March 2025. Cambridge Arthritis Research Endeavour is abbreviated to CARE in the report below.

The financial statements have been prepared in accordance with the accounting policies set out in note 2 to the financial statements and comply with the Charity's trust deed, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

#### **Objectives and activities**

The purpose and work of CARE is primarily in the field of arthritis and relief and education concerning such conditions.

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

The Trustees believe that the Charity's research is of huge benefit to the public. The Charity was formed by a Trust Deed dated 29 January 1990. (Charity number 802862).

Since it is essentially a medical charity, it is appropriate that most of the Trustees are medical. In setting up the charity it was recognised that it was important to have a balanced mix of Trustees. The initial mix was mainly medical with a fundraiser and a lawyer.

As Trustees have resigned and replacements needed, the broad focus has been on replacing like with like, so a medical Trustee on leaving has been replaced by an incoming medical Trustee. The Board of Trustees have felt this to be in line with the original intent of the charity. In appointing Trustees, the Board has focussed on finding Trustees, who, not only have excellent credentials, but who would also be able to make a significant contribution to the work of CARE. The Trustees intend to appoint additional trustees with legal and/or financial expertise in due course.

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

#### **Achievements and performance**

CARE administrates the academic and commercial research studies conducted in the rheumatology research unit (RRU). This includes: sourcing and accepting grants and other funds to perform the research; paying salaries of the research doctors, nurses, practitioners and administrators (under the auspices of their employer, Cambridge University Hospitals NHSFT); paying for equipment, consumables and training required to perform the research duties.

The Rheumatology Research Unit (RRU) comprises a senior administrator, 3 research nurses, 1 research nurse practitioner and a research fellow who has registered for an MD. Over the past year, the RRU has launched 5 new studies (MARASLE, BE-BOLD, TAILOR, SAGE and BxSICs) and is continuing to recruit to a number of existing Commercial and Academic studies and Registries. Studies have recruited patients with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Stickler Syndrome, Giant Cell Arteritis, Complex Regional Pain Syndrome and Sjogren's Syndrome. Early phase studies and late phase studies provide NHS patients with access to novel therapies, some of which will be years before they are available to the general public. Our hope is to provide access to therapies, support the NHS and better understand the genetics and biology of these diseases.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

**Dr Shenker** has an interest in chronic pain syndromes and leads the clinical service for diagnosing patients with Complex Regional Pain Syndromes (CRPS) and related conditions, collaborating with other Specialist Services within Addenbrooke's Hospital. He is Chair of the CRPS-UK Network and Registry. His research interests relate to this patient cohort and he actively recruits patients for studies in basic science (Genetics, Imaging, Neurophysiological) along with an innovative rehabilitation strategy using a Virtual Environment. Parallel to this Dr Shenker is looking at patients with active Rheumatoid Arthritis due to receive anti-TNF treatment. The study will use a 7T MRI scan to look at the brain before and after the anti-TNF therapy to investigate the improvements in general wellbeing often reported in patients with this treatment.

**Dr Frances Hall** has an interest in Connective Tissue Disease (CTD). Dr Hall chaired the SALVE (Scleroderma App for Lesion Verification) working group (November 2020-November 2023), sponsored by University of Manchester. This developed an application for capturing images and metrics relating to digital ulceration in systemic sclerosis. An app which enables patient-led data capture of high-quality images for evaluation of changes in digital ulcers, would provide a powerful vehicle for data capture in clinical trials and in clinical practice. Dr Hall is also a collaborator on the sequel project APPRAISE (Assessment of Photographic Ulcer Recognition and Analysis in Systemic Sclerosis Evaluation). This will start in 2025 and will compare scoring of images of digital ulcers by the SALVE App with scores from expert human evaluators.

In 2024, Dr Hall collaborated with Alain Amstutz (Basel University) on a meta-analysis of 16 clinical trials evaluating JAK inhibitors in COVID-19. During the pandemic, Dr Hall was Chief Investigator on a national clinical trial (TACTIC-R) of Baricitinib (JAK inhibitor) and Ravulizumab (Complement C5 inhibitor). The TACTIC-R Trial Management Group shared the data from the control and baricitinib arms of the TACTIC-R trial with the Basel team. This concluded that benefit was evident across a range of JAK inhibitors in COVID-19 and associated Interstitial Lung Disease (ILD) and ran a trial which showed that lung volumes increased and quality of life improved after treatment with an immunosuppressant, rituximab, and this treatment is now available to these patients.

**Prof Andrew McCaskie** is Professor of orthopaedics and directs the Versus Arthritis; Tissue Engineering and Regenerative Therapies Centre, investigating the use of stem cell therapies in joint disease. His clinical interest is lower limb, particularly hip disease in young patients. He also conducts clinical trials using cell therapy trial for knee arthritis.

#### Financial review

Fixed asset investments are showing a loss of £24,945 (2024 - gain of £61,929) during the year and generated spendable income of £21,416 (2024 - £27,865), which the Trustees consider to be satisfactory performance.

It is the policy of the Charity that unrestricted funds which have not been designated for a specific use should be maintained at a level which is adequate to meet the charity's objectives. The Charity has a reserves policy to not let these funds fall below £500K.

The results for the year are set out in the attached financial statements. At the balance sheet date the Charity had total net assets less current liabilities of £385,725 (2024 - £568,431). The Charity reserves amounted to £300,303 (2024 - £482,678).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

The Trustees have conducted their own review of the major risks to which the Charity is exposed and systems have been established to mitigate those risks. Procedures have been put in place to minimise both the external and internal risks and these procedures are periodically reviewed to ensure that they still meet the needs of the Charity.

The risks are largely defined as being financial and/or medical. Financially, the Charity has taken professional advice and its finances are handled by CCLA Investment Management Ltd with part of its cash invested in Units and part invested on term deposits. Overall the Charity is seeking to ensure that there is approximately five years of anticipated funding needs in its reserves (or such reserves as may be advised by the Charity Commission); the five years funding in reserves is an aspiration at the moment. Steps are being taken on the fund-raising front to enhance the level of reserves.

Medically, the Charity is exposed to risk in the following ways:

*1. The CARE website*

The CARE website has been reconstructed.

*2. CARE Speaker and Social Meetings*

These events bring together members of the Rheumatology Department and patients, with their relatives and friends. Venues selected are used regularly for conferences and present no unusual hazard. Several medical members of the team are present at these events, should medical attention be required.

*3. CARE involvement in scientific research and clinical trials*

All scientific research sponsored by CARE is conducted under the ethical and management policies of Cambridge University Hospitals NHS Foundation Trust (CUHNHSFT) (to whom proposals are submitted for peer review). Where CARE staff participate in clinical trials, these are normally conducted on behalf of pharmaceutical companies, or their agents, and therefore subject to the normal regulatory processes. Where CARE sponsors clinical trials directly, these are conducted under the regulations set out by CUHNHSFT, and are subject to ethical review. Insurance against adverse outcomes in any CARE-instigated clinical trial is provided through CUHNHSFT.

### **Structure, governance and management**

The Governing document of the Charity is a Declaration of Trust dated 29 January 1990.

The address of the charity is:

Box 194 Unit E6  
Addenbrookes Hospital  
Hills Road  
Cambridge  
Cams  
CB2 0QQ

The Trustees who served during the year and up to the date of signature of the financial statements were:

Professor H Gaston  
Dr N Shenker  
Dr F Hall  
Professor A McCaskie  
S Hartshorn  
S Ramsay  
His Honour Christopher Hodson

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

*FOR THE YEAR ENDED 31 MARCH 2025*

---

Prospective and newly appointed Trustees are given a detailed understanding of the research work carried out by CARE, so that those who are invited to join are conversant with what is expected of them.

In planning for the coming year, the Trustees agree the framework in which CARE will operate and the day-to-day detail to achieve this is delegated to the staff of CARE. Should the staff wish to change the framework, then an approach is made to the Trustees to seek their authority to make the changes.

The day to day affairs of the charity are run by the Administrator.

The charity's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.

The Trustees' report was approved by the Board of Trustees.

Professor H Gaston  
**Trustee**

30 November 2025

# **CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR**

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

***FOR THE YEAR ENDED 31 MARCH 2025***

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

---

I report to the Trustees on my examination of the financial statements of Cambridge Arthritis Research Endeavour (the Charity) for the year ended 31 March 2025.

#### **Responsibilities and basis of report**

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011.

I report in respect of my examination of the Charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

#### **Independent examiner's statement**

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn. I understand that this has been done in order for the financial statements to provide a true and fair view in accordance with UK Generally Accepted Accounting Practice.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the Charity as required by section 130 of the Charities Act 2011.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of financial statements set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Ms J Boatfield FCA, DChA  
Ensors

First Floor  
Victory House, Vision Park  
Chivers Way, Histon  
Cambridge  
CB24 9ZR

Dated: 1 December 2025

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

**FOR THE YEAR ENDED 31 MARCH 2025**

|   | Notes | Unrestricted<br>funds<br>2025<br>£ | Restricted<br>funds<br>2025<br>£ | Total<br>2025<br>£    | Unrestricted<br>funds<br>2024<br>£ | Restricted<br>funds<br>2024<br>£ | Total<br>2024<br>£    |
|---|-------|------------------------------------|----------------------------------|-----------------------|------------------------------------|----------------------------------|-----------------------|
| <b>Income from:</b>                                   |       |                                    |                                  |                       |                                    |                                  |                       |
| Donations and legacies                                | 3     | 865                                | -                                | 865                   | 1,694                              | -                                | 1,694                 |
| Charitable activities                                 | 4     | 23,432                             | 30,000                           | 53,432                | 30,692                             | 55,097                           | 85,789                |
| Investments   | 5     | 23,544                             | -                                | 23,544                | 30,360                             | -                                | 30,360                |
| <b>Total income</b>                                   |       | <u>47,841</u>                      | <u>30,000</u>                    | <u>77,841</u>         | <u>62,746</u>                      | <u>55,097</u>                    | <u>117,843</u>        |
| <b>Expenditure on:</b>                                |       |                                    |                                  |                       |                                    |                                  |                       |
| Charitable activities                                 | 6     | 207,531                            | 28,371                           | 235,902               | 240,185                            | 33,071                           | 273,256               |
| Net gains/(losses) on investments                     | 10    | (24,645)                           | -                                | (24,645)              | 61,929                             | -                                | 61,929                |
| <b>Net income/(expenditure) and movement in funds</b> |       | <u>(184,335)</u>                   | <u>1,629</u>                     | <u>(182,706)</u>      | <u>(115,510)</u>                   | <u>22,026</u>                    | <u>(93,484)</u>       |
| <b>Reconciliation of funds:</b>                       |       |                                    |                                  |                       |                                    |                                  |                       |
| Fund balances at 1 April 2024                         |       | <u>493,546</u>                     | <u>74,885</u>                    | <u>568,431</u>        | <u>609,056</u>                     | <u>52,859</u>                    | <u>661,915</u>        |
| <b>Fund balances at 31 March 2025</b>                 |       | <u><u>309,211</u></u>              | <u><u>76,514</u></u>             | <u><u>385,725</u></u> | <u><u>493,546</u></u>              | <u><u>74,885</u></u>             | <u><u>568,431</u></u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET

AS AT 31 MARCH 2025

|   | Notes | 2025<br>£      | £                | 2024<br>£      | £                |
|---|-------|----------------|------------------|----------------|------------------|
| <b>Fixed assets</b>                                   |       |                |                  |                |                  |
| Tangible assets                                       | 13    |                | 8,858            |                | 10,818           |
| Investments   | 14    |                | 569,798          |                | 873,026          |
|   |       |                | <u>578,656</u>   |                | <u>883,844</u>   |
| <b>Current assets</b>                                 |       |                |                  |                |                  |
| Debtors   | 15    | 129,754        |                  | 146,627        |                  |
| Cash at bank and in hand                              |       | 87,799         |                  | 74,600         |                  |
|   |       | <u>217,553</u> |                  | <u>221,227</u> |                  |
| <b>Creditors: amounts falling due within one year</b> | 16    | (410,484)      |                  | (536,640)      |                  |
| Net current liabilities                               |       |                | <u>(192,931)</u> |                | <u>(315,413)</u> |
| <b>Total assets less current liabilities</b>          |       |                | <u>385,725</u>   |                | <u>568,431</u>   |
| <b>Income funds</b>                                   |       |                |                  |                |                  |
| Restricted funds                                      | 17    |                | 76,514           |                | 74,885           |
| Unrestricted funds                                    |       |                |                  |                |                  |
| General unrestricted funds                            |       | 309,161        |                  | 493,496        |                  |
| Trustees' subscriptions                               |       | 50             |                  | 50             |                  |
|   |       | <u>309,211</u> |                  | <u>493,546</u> |                  |
|   |       |                | <u>385,725</u>   |                | <u>568,431</u>   |

The financial statements were approved by the Trustees on 30 November 2025

Professor H Gaston  
Trustee

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2025

---

### 1 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 2 Accounting policies

#### Charity information

Cambridge Arthritis Research Endeavour is a Registered Charity governed by a declaration of trust dated 29 January 1980. Its objectives are the relief of persons who are suffering from rheumatoid arthritis and related diseases and to promote and advance medical research and education concerning such disorders provided that the useful results of such research shall be published.

#### 2.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's declaration of trust, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The Charity is a Public Benefit Entity as defined by FRS 102.

The Charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 2.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 2.3 Charitable funds

Resources received are allocated to restricted funds according to the limitations specified on their use by the donors or other providers. Funds which can be used for general purposes of the Charity are treated as unrestricted.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

---

### 2 Accounting policies

(Continued)

#### 2.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacy income is recognised when the following conditions have been met: the final estate accounts have been approved, the legacy is capable of measurement and there is no reversionary interest.

Grants received for use in purchasing capital items are included as income within restricted funds and are reduced each year by an amount equivalent to depreciation of those assets.

Revenue grants are recognised when there is evidence of entitlement to the grant, receipt is probable and the amount can be measured reliably.

Income from drug trials is recognised when it is probable the payment will be received and can be measured accurately.

#### 2.5 Resources expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

#### 2.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

|                       |                         |
|-----------------------|-------------------------|
| Fixtures and fittings | 15% straight line basis |
|-----------------------|-------------------------|

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

#### 2.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

#### 2.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

---

### 2 Accounting policies

(Continued)

#### 2.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

### 3 Donations and legacies

|                     | <b>Unrestricted<br/>funds</b> | Unrestricted<br>funds |
|---------------------|-------------------------------|-----------------------|
|                     | <b>2025</b>                   | 2024                  |
|                     | £                             | £                     |
| Donations and gifts | 865                           | 1,694                 |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

---

### 4 Charitable activities

|                    | 2025<br>£     | 2024<br>£     |
|--------------------|---------------|---------------|
| Grants             | 30,000        | 55,097        |
| Drug trial income  | 23,432        | 30,692        |
|                    | <u>53,432</u> | <u>85,789</u> |
| Analysis by fund   |               |               |
| Unrestricted funds | 23,432        | 30,692        |
| Restricted funds   | 30,000        | 55,097        |
|                    | <u>53,432</u> | <u>85,789</u> |

### 5 Investment income

|               | Unrestricted<br>funds<br>2025<br>£ | Unrestricted<br>funds<br>2024<br>£ |
|---------------|------------------------------------|------------------------------------|
| COIF          | 21,416                             | 27,865                             |
| Bank interest | 2,128                              | 2,495                              |
|               | <u>23,544</u>                      | <u>30,360</u>                      |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 6 Expenditure on charitable activities

|   | Charitable<br>activities<br>2025<br>£ | Charitable<br>activities<br>2024<br>£ |
|---|---------------------------------------|---------------------------------------|
| <b>Direct costs</b>                                       |                                       |                                       |
| Staff costs   | 167,395                               | 213,865                               |
| Depreciation and impairment                               | 1,960                                 | 2,112                                 |
| Archiving   | 467                                   | 253                                   |
| Conferences and travel                                    | -                                     | 1,239                                 |
| Drug trials   | (1,602)                               | (5,538)                               |
| Patient travel  | -                                     | (162)                                 |
| Trial costs for genomic extraction                        | 14,209                                | 16,896                                |
| Insurance   | 549                                   | 339                                   |
| Stationery and computer supplies                          | 887                                   | 586                                   |
| Sundry expenses   | 713                                   | 974                                   |
| Bank charges  | 116                                   | 124                                   |
| Maintenance   | 187                                   | 193                                   |
| Research  | 713                                   | 2,421                                 |
| Irrecoverable VAT   | 484                                   | 3,950                                 |
|   | <u>186,078</u>                        | <u>237,252</u>                        |
| <b>Share of support and governance costs (see note 7)</b> |                                       |                                       |
| Support   | 34,405                                | 23,009                                |
| Governance  | 15,419                                | 12,995                                |
|   | <u>235,902</u>                        | <u>273,256</u>                        |
| <b>Analysis by fund</b>                                   |                                       |                                       |
| Unrestricted funds  | 207,531                               | 240,185                               |
| Restricted funds  | 28,371                                | 33,071                                |
|   | <u>235,902</u>                        | <u>273,256</u>                        |

### 7 Support costs allocated to activities

|                          | 2025<br>£     | 2024<br>£     |
|--------------------------|---------------|---------------|
| Staff costs              | 34,405        | 23,009        |
| Governance costs         | 15,419        | 12,995        |
|                          | <u>49,824</u> | <u>36,004</u> |
| <b>Analysed between:</b> |               |               |
| Charitable activities    | <u>49,824</u> | <u>36,004</u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

---

|          |                              |             |             |
|----------|------------------------------|-------------|-------------|
| <b>8</b> | <b>Net movement in funds</b> | <b>2025</b> | <b>2024</b> |
|          |                              | <b>£</b>    | <b>£</b>    |

The net movement in funds is stated after charging/(crediting):

|  |                   |                   |
|--|-------------------|-------------------|
| Fees payable for the independent examination of the charity's financial statements | 750               | 725               |
| Depreciation of owned tangible fixed assets  | 1,960             | 2,112             |
|  | <u>          </u> | <u>          </u> |

### 9 Trustees

During the year, no Trustees received any remuneration (2024 - £nil), benefits in kind (2024 - £nil) or reimbursement of expenses (2024 - £nil) in relation to their role as Trustees.

### 10 Gains and losses on investments

|   | <b>Unrestricted funds</b> | <b>Unrestricted funds</b> |
|---|---------------------------|---------------------------|
|   | <b>2025</b>               | <b>2024</b>               |
|   | <b>£</b>                  | <b>£</b>                  |
| Gains/(losses) arising on:              |                           |                           |
| Revaluation and disposal of investments | (24,645)                  | 61,929                    |
|   | <u>          </u>         | <u>          </u>         |

### 11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

### 12 Employees

There were no employees during the year.

|   |                   |                   |
|---|-------------------|-------------------|
| <b>Employment costs</b>   | <b>2025</b>       | <b>2024</b>       |
|   | <b>£</b>          | <b>£</b>          |
| Wages and salaries recharged from Cambridge University Hospitals NHS Foundation Trust | 213,269           | 244,544           |
|   | <u>          </u> | <u>          </u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### 13 Tangible fixed assets

|                                    | Fixtures and fittings<br>£ |
|------------------------------------|----------------------------|
| <b>Cost</b>                        |                            |
| At 1 April 2024                    | 57,641                     |
| At 31 March 2025                   | 57,641                     |
| <b>Depreciation and impairment</b> |                            |
| At 1 April 2024                    | 46,823                     |
| Depreciation charged in the year   | 1,960                      |
| At 31 March 2025                   | 48,783                     |
| <b>Carrying amount</b>             |                            |
| At 31 March 2025                   | 8,858                      |
| At 31 March 2024                   | 10,818                     |

### 14 Fixed asset investments

|  | COIF Units<br>£ | Deposit Fund<br>- Capital<br>£ | Deposit Fund<br>- Income<br>£ | Total<br>£ |
|--|-----------------|--------------------------------|-------------------------------|------------|
| <b>Cost or valuation</b>               |                 |                                |                               |            |
| At 1 April 2024                        | 683,140         | 7,023                          | 182,863                       | 873,026    |
| Income retained in COIF Income Account | -               | -                              | 21,417                        | 21,417     |
| Gain/ (loss)                           | (24,645)        | -                              | -                             | (24,645)   |
| Disposals                              | (100,000)       | (5,000)                        | (195,000)                     | (300,000)  |
| At 31 March 2025                       | 558,495         | 2,023                          | 9,280                         | 569,798    |
| <b>Carrying amount</b>                 |                 |                                |                               |            |
| At 31 March 2025                       | 558,495         | 2,023                          | 9,280                         | 569,798    |
| At 31 March 2024                       | 683,140         | 7,023                          | 182,863                       | 873,026    |

### 15 Debtors

|   | 2025<br>£ | 2024<br>£ |
|---|-----------|-----------|
| <b>Amounts falling due within one year:</b> |           |           |
| Trade debtors                               | 125,659   | 136,383   |
| Other debtors                               | 656       | 656       |
| Prepayments and accrued income              | 3,439     | 9,588     |
|   | 129,754   | 146,627   |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

#### 16 Creditors: amounts falling due within one year

|                                    | 2025<br>£      | 2024<br>£      |
|------------------------------------|----------------|----------------|
| Other taxation and social security | 9,978          | 12,767         |
| Trade creditors                    | 38,198         | 8,318          |
| Other creditors                    | 352,132        | 503,902        |
| Accruals and deferred income       | 10,176         | 11,653         |
|                                    | <u>410,484</u> | <u>536,640</u> |

#### 17 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

|               | At 1 April<br>2024<br>£ | Incoming<br>resources<br>£ | Resources<br>expended<br>£ | At 31 March<br>2025<br>£ |
|---------------|-------------------------|----------------------------|----------------------------|--------------------------|
| Classic Study | 3,350                   | -                          | -                          | 3,350                    |
| XLH Study     | 45,320                  | -                          | (10,783)                   | 34,537                   |
| PPIE Project  | 2,000                   | -                          | -                          | 2,000                    |
| BSR Funding   | 24,215                  | -                          | (4,588)                    | 19,627                   |
| Realise Study | -                       | 30,000                     | (13,000)                   | 17,000                   |
|               | <u>74,885</u>           | <u>30,000</u>              | <u>(28,371)</u>            | <u>76,514</u>            |

#### Previous year:

|               | At 1 April<br>2023<br>£ | Incoming<br>resources<br>£ | Resources<br>expended<br>£ | At 31 March<br>2024<br>£ |
|---------------|-------------------------|----------------------------|----------------------------|--------------------------|
| Classic Study | 3,350                   | -                          | -                          | 3,350                    |
| XLH Study     | 26,958                  | 34,536                     | (16,175)                   | 45,319                   |
| PPIE Project  | 2,000                   | -                          | -                          | 2,000                    |
| BSR Funding   | 20,551                  | 20,561                     | (16,896)                   | 24,216                   |
|               | <u>52,859</u>           | <u>55,097</u>              | <u>(33,071)</u>            | <u>74,885</u>            |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

#### 18 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

|                       | At 1 April<br>2024<br>£          | Incoming<br>resources<br>£          | Resources<br>expended<br>£          | Gains and<br>losses<br>£          | At 31 March<br>2025<br>£          |
|-----------------------|----------------------------------|-------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|
| General funds         | 493,496                          | 47,841                              | (207,531)                           | (24,645)                          | 309,161                           |
|                       | <u>493,496</u>                   | <u>47,841</u>                       | <u>(207,531)</u>                    | <u>(24,645)</u>                   | <u>309,161</u>                    |
| <b>Previous year:</b> | <b>At 1 April<br/>2023<br/>£</b> | <b>Incoming<br/>resources<br/>£</b> | <b>Resources<br/>expended<br/>£</b> | <b>Gains and<br/>losses<br/>£</b> | <b>At 31 March<br/>2024<br/>£</b> |
| General funds         | 609,006                          | 62,746                              | (240,185)                           | 61,929                            | 493,496                           |
|                       | <u>609,006</u>                   | <u>62,746</u>                       | <u>(240,185)</u>                    | <u>61,929</u>                     | <u>493,496</u>                    |

#### 19 Analysis of net assets between funds

|   | Unrestricted<br>funds<br>2025<br>£ | Restricted<br>funds<br>2025<br>£ | Total<br>2025<br>£ |
|---|------------------------------------|----------------------------------|--------------------|
| <b>Fund balances at 31 March 2025 are represented by:</b> |                                    |                                  |                    |
| Tangible assets   | 8,858                              | -                                | 8,858              |
| Investments   | 569,798                            | -                                | 569,798            |
| Current assets/(liabilities)                              | (269,445)                          | 76,514                           | (192,931)          |
|   | <u>309,211</u>                     | <u>76,514</u>                    | <u>385,725</u>     |
|   | <u>309,211</u>                     | <u>76,514</u>                    | <u>385,725</u>     |
|   | Unrestricted<br>funds<br>2024<br>£ | Restricted<br>funds<br>2024<br>£ | Total<br>2024<br>£ |
| <b>Fund balances at 31 March 2024 are represented by:</b> |                                    |                                  |                    |
| Tangible assets   | 10,818                             | -                                | 10,818             |
| Investments   | 873,026                            | -                                | 873,026            |
| Current assets/(liabilities)                              | (390,298)                          | 74,885                           | (315,413)          |
|   | <u>493,546</u>                     | <u>74,885</u>                    | <u>568,431</u>     |
|   | <u>493,546</u>                     | <u>74,885</u>                    | <u>568,431</u>     |

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR (CARE)**

England & Wales - Charity number 802862

---

# Accounts

---

Charity registration number 802862

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR  
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024**

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## LEGAL AND ADMINISTRATIVE INFORMATION

---

|                             |   |
|-----------------------------|---|
| <b>Trustees</b>             | Professor H Gaston<br>Dr N Shenker<br>Dr F Hall<br>Professor A McCaskie<br>S Hartshorn<br>S Ramsay<br>His Honour Christopher Hodson |
| <b>Charity number</b>       | 802862  |
| <b>Registered office</b>    | Box 194 Unit E6<br>Addenbrookes Hospital<br>Hills Road<br>Cambridge<br>CB2 0QQ  |
| <b>Independent examiner</b> | Ms J Boatfield FCA, DChA<br>Ensors Accountants LLP<br>Victory House<br>Vision Park<br>Histon<br>Cambridge<br>CB24 9ZR               |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## CONTENTS

---

|   | <b>Page</b> |
|---|-------------|
| Trustees' report                        | 1 - 4       |
| Statement of Trustees' responsibilities | 5           |
| Independent examiner's report           | 6           |
| Statement of financial activities       | 7           |
| Balance sheet                           | 8           |
| Notes to the financial statements       | 9 - 17      |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 MARCH 2024

---

The Trustees present their annual report and financial statements for the year ended 31 March 2024. Cambridge Arthritis Research Endeavour is abbreviated to CARE in the report below.

The financial statements have been prepared in accordance with the accounting policies set out in note 2 to the financial statements and comply with the Charity's trust deed, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

#### **Objectives and activities**

The purpose and work of CARE is primarily in the field of arthritis and relief and education concerning such conditions.

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

The Trustees believe that the Charity's research is of huge benefit to the public. The Charity was formed by a Trust Deed dated 29 January 1990. (Charity number 802862).

Since it is essentially a medical charity, it is appropriate that most of the Trustees are medical. In setting up the charity it was recognised that it was important to have a balanced mix of Trustees. The initial mix was mainly medical with a fundraiser and a lawyer.

As Trustees have resigned and replacements needed, the broad focus has been on replacing like with like, so a medical Trustee on leaving has been replaced by an incoming medical Trustee. The Board of Trustees have felt this to be in line with the original intent of the charity. In appointing Trustees, the Board has focussed on finding Trustees, who, not only have excellent credentials, but who would also be able to make a significant contribution to the work of CARE. The Trustees intend to appoint additional trustees with legal and/or financial expertise in due course.

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

#### **Achievements and performance**

CARE administrates the academic and commercial research studies conducted in the rheumatology research unit (RRU). This includes: sourcing and accepting grants and other funds to perform the research; paying salaries of the research doctors, nurses, practitioners and administrators (under the auspices of their employer, Cambridge University Hospitals NHSFT); paying for equipment, consumables and training required to perform the research duties.

At the beginning of 2022 we were able to restart a number of research studies following the covid pandemic. The current team comprises a senior administrator, research nurse manager, four research nurses and a research nurse practitioner. CARE has also funded several research fellows (senior doctors undertaking a period of research).

The RRU team is continuing to recruit to a number of studies and has continually met the recruitment targets. Between 2022 and 2023 we successfully recruited to an interventional clinical trial of a novel biologic therapy for osteoarthritis of the knee, led by the pharmaceutical company GlaxoSmithKline (GSK). In 2023 we started recruitment to the Immune Mediated Inflammatory Disease (IMID) study, looking at patients with RA, PsA, axial spondyloarthritis, lupus (SLE), Sjogren's syndrome, systemic sclerosis, myositis and skin psoriasis. Our hope is to better understand the genetics and biology of these diseases.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2024

---

**Dr Shenker** has an interest in chronic pain syndromes and leads the clinical service for diagnosing patients with Complex Regional Pain Syndromes (CRPS) and related conditions, collaborating with other Specialist Services within Addenbrooke's Hospital. He is Chair of the CRPS-UK Network and Registry. His research interests relate to this patient cohort and he actively recruits patients for studies in basic science (Genetics, Imaging, Neurophysiological) along with an innovative rehabilitation strategy using a Virtual Environment. Parallel to this Dr Shenker is looking at patients with active Rheumatoid Arthritis due to receive anti-TNF treatment. The study will use a 7T MRI scan to look at the brain before and after the anti-TNF therapy to investigate the improvements in general wellbeing often reported in patients with this treatment.

**Dr Frances Hall** has an interest in Connective Tissue Disease (CTD). Dr Hall chaired the SALVE (Scleroderma App for Lesion Verification) working group (November 2020-November 2023), sponsored by University of Manchester. This developed an application for capturing images and metrics relating to digital ulceration in systemic sclerosis. An app which enables patient-led data capture of high-quality images for evaluation of changes in digital ulcers, would provide a powerful vehicle for data capture in clinical trials and in clinical practice. Dr Hall is also a collaborator on the sequel project APPRAISE (Assessment of Photographic Ulcer Recognition and Analysis in Systemic Sclerosis Evaluation). This will start in 2025 and will compare scoring of images of digital ulcers by the SALVE App with scores from expert human evaluators.

In 2024, Dr Hall collaborated with Alain Amstutz (Basel University) on a meta-analysis of 16 clinical trials evaluating JAK inhibitors in COVID-19. During the pandemic, Dr Hall was Chief Investigator on a national clinical trial (TACTIC-R) of Baricitinib (JAK inhibitor) and Ravulizumab (Complement C5 inhibitor). The TACTIC-R Trial Management Group shared the data from the control and baricitinib arms of the TACTIC-R trial with the Basel team. This concluded that benefit was evident across a range of JAK inhibitors in COVID-19 and associated Interstitial Lung Disease (ILD) and ran a trial which showed that lung volumes increased and quality of life improved after treatment with an immunosuppressant, rituximab, and this treatment is now available to these patients.

**Prof Andrew McCaskie** is Professor of orthopaedics and directs the Versus Arthritis; Tissue Engineering and Regenerative Therapies Centre, investigating the use of stem cell therapies in joint disease. His clinical interest is lower limb, particularly hip disease in young patients. He also conducts clinical trials using cell therapy trial for knee arthritis.

#### Financial review

Fixed asset investments are showing an unrealised gain of £61,929 (2023 - loss of £32,310) during the year and generated spendable income of £27,865 (2023 - £22,044), which the Trustees consider to be satisfactory performance.

It is the policy of the Charity that unrestricted funds which have not been designated for a specific use should be maintained at a level which is adequate to meet the charity's objectives. The Charity has a reserves policy to not let these funds fall below £500K.

The results for the year are set out in the attached financial statements. At the balance sheet date the Charity had total net assets less current liabilities of £568,431 (2023 - £661,915). The Charity reserves amounted to £482,678 (2023 - £608,398).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2024

---

The Trustees have conducted their own review of the major risks to which the Charity is exposed and systems have been established to mitigate those risks. Procedures have been put in place to minimise both the external and internal risks and these procedures are periodically reviewed to ensure that they still meet the needs of the Charity.

The risks are largely defined as being financial and/or medical. Financially, the Charity has taken professional advice and its finances are handled by CCLA Investment Management Ltd with part of its cash invested in Units and part invested on term deposits. Overall the Charity is seeking to ensure that there is approximately five years of anticipated funding needs in its reserves (or such reserves as may be advised by the Charity Commission); the five years funding in reserves is an aspiration at the moment. Steps are being taken on the fund-raising front to enhance the level of reserves.

Medically, the Charity is exposed to risk in the following ways:

*1. The CARE website*

The CARE website has been reconstructed.

*2. CARE Speaker and Social Meetings*

These events bring together members of the Rheumatology Department and patients, with their relatives and friends. Venues selected are used regularly for conferences and present no unusual hazard. Several medical members of the team are present at these events, should medical attention be required.

*3. CARE involvement in scientific research and clinical trials*

All scientific research sponsored by CARE is conducted under the ethical and management policies of Cambridge University Hospitals NHS Foundation Trust (CUHNHSFT) (to whom proposals are submitted for peer review). Where CARE staff participate in clinical trials, these are normally conducted on behalf of pharmaceutical companies, or their agents, and therefore subject to the normal regulatory processes. Where CARE sponsors clinical trials directly, these are conducted under the regulations set out by CUHNHSFT, and are subject to ethical review. Insurance against adverse outcomes in any CARE-instigated clinical trial is provided through CUHNHSFT.

### **Structure, governance and management**

The Governing document of the Charity is a Declaration of Trust dated 29 January 1990.

The address of the charity is:

Box 194 Unit E6  
Addenbrookes Hospital  
Hills Road  
Cambridge  
Cams  
CB2 0QQ

The Trustees who served during the year and up to the date of signature of the financial statements were:

Professor H Gaston  
Dr N Shenker  
Dr F Hall  
Professor A McCaskie  
S Hartshorn  
S Ramsay  
His Honour Christopher Hodson  
Dr D Jadon

(Deceased 17 November 2023)

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### *FOR THE YEAR ENDED 31 MARCH 2024*

---

Prospective and newly appointed Trustees are given a detailed understanding of the research work carried out by CARE, so that those who are invited to join are conversant with what is expected of them.

In planning for the coming year, the Trustees agree the framework in which CARE will operate and the day-to-day detail to achieve this is delegated to the staff of CARE. Should the staff wish to change the framework, then an approach is made to the Trustees to seek their authority to make the changes.

The day to day affairs of the charity are run by the Administrator.

The charity's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.

The Trustees' report was approved by the Board of Trustees.

Professor H Gaston  
**Trustee**

9 December 2024

# **CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR**

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

***FOR THE YEAR ENDED 31 MARCH 2024***

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

---

I report to the Trustees on my examination of the financial statements of Cambridge Arthritis Research Endeavour (the Charity) for the year ended 31 March 2024.

#### **Responsibilities and basis of report**

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the Charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### **Independent examiner's statement**

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Ms J Boatfield FCA, DChA  
Ensors Accountants LLP

Victory House  
Vision Park  
Chivers Way, Histon  
Cambridge  
CB24 9ZR

Dated: 11 December 2024

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

**FOR THE YEAR ENDED 31 MARCH 2024**

|                                       | Notes | Unrestricted<br>funds<br>2024<br>£ | Restricted<br>funds<br>2024<br>£ | Total<br>2024<br>£    | Unrestricted<br>funds<br>2023<br>£ | Restricted<br>funds<br>2023<br>£ | Total<br>2023<br>£    |
|---------------------------------------|-------|------------------------------------|----------------------------------|-----------------------|------------------------------------|----------------------------------|-----------------------|
| <b>Income from:</b>                   |       |                                    |                                  |                       |                                    |                                  |                       |
| Donations and legacies                | 3     | 1,694                              | -                                | 1,694                 | 180,667                            | -                                | 180,667               |
| Charitable activities                 | 4     | 30,692                             | 55,097                           | 85,789                | 37,096                             | 54,901                           | 91,997                |
| Investments                           | 5     | 30,360                             | -                                | 30,360                | 22,259                             | -                                | 22,259                |
| <b>Total income</b>                   |       | <u>62,746</u>                      | <u>55,097</u>                    | <u>117,843</u>        | <u>240,022</u>                     | <u>54,901</u>                    | <u>294,923</u>        |
| <b>Expenditure on:</b>                |       |                                    |                                  |                       |                                    |                                  |                       |
| Charitable activities                 | 6     | 240,185                            | 33,071                           | 273,256               | 166,909                            | 25,678                           | 192,587               |
| Net gains/(losses) on investments     | 10    | 61,929                             | -                                | 61,929                | (32,310)                           | -                                | (32,310)              |
| <b>Net income/(expenditure)</b>       |       | <u>(115,510)</u>                   | <u>22,026</u>                    | <u>(93,484)</u>       | <u>40,803</u>                      | <u>29,223</u>                    | <u>70,026</u>         |
| Transfers between funds               |       | -                                  | -                                | -                     | 48,091                             | (48,091)                         | -                     |
| <b>Net movement in funds</b>          | 8     | <u>(115,510)</u>                   | <u>22,026</u>                    | <u>(93,484)</u>       | <u>88,894</u>                      | <u>(18,868)</u>                  | <u>70,026</u>         |
| <b>Reconciliation of funds:</b>       |       |                                    |                                  |                       |                                    |                                  |                       |
| Fund balances at 1 April 2023         |       | <u>609,056</u>                     | <u>52,859</u>                    | <u>661,915</u>        | <u>520,162</u>                     | <u>71,727</u>                    | <u>591,889</u>        |
| <b>Fund balances at 31 March 2024</b> |       | <u><u>493,546</u></u>              | <u><u>74,885</u></u>             | <u><u>568,431</u></u> | <u><u>609,056</u></u>              | <u><u>52,859</u></u>             | <u><u>661,915</u></u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET

AS AT 31 MARCH 2024

|   | Notes | 2024           |                  | 2023           |                  |
|---|-------|----------------|------------------|----------------|------------------|
|   |       | £              | £                | £              | £                |
| <b>Fixed assets</b>                                   |       |                |                  |                |                  |
| Tangible assets                                       | 13    |                | 10,818           |                | 608              |
| Investments   | 14    |                | 873,026          |                | 883,232          |
|   |       |                | <u>883,844</u>   |                | <u>883,840</u>   |
| <b>Current assets</b>                                 |       |                |                  |                |                  |
| Debtors   | 15    | 146,627        |                  | 185,047        |                  |
| Cash at bank and in hand                              |       | 74,600         |                  | 127,360        |                  |
|   |       | <u>221,227</u> |                  | <u>312,407</u> |                  |
| <b>Creditors: amounts falling due within one year</b> | 16    | (536,640)      |                  | (534,332)      |                  |
| Net current liabilities                               |       |                | <u>(315,413)</u> |                | <u>(221,925)</u> |
| <b>Total assets less current liabilities</b>          |       |                | <u>568,431</u>   |                | <u>661,915</u>   |
| <b>Income funds</b>                                   |       |                |                  |                |                  |
| Restricted funds                                      | 17    |                | 74,885           |                | 52,859           |
| Unrestricted funds                                    |       |                |                  |                |                  |
| General unrestricted funds                            |       | 493,496        |                  | 609,006        |                  |
| Trustees' subscriptions                               |       | 50             |                  | 50             |                  |
|   |       | <u>493,546</u> |                  | <u>609,056</u> |                  |
|   |       |                | <u>568,431</u>   |                | <u>661,915</u>   |

The financial statements were approved by the Trustees on 9 December 2024

Professor H Gaston  
Trustee

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2024

---

### 1 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 2 Accounting policies

#### Charity information

Cambridge Arthritis Research Endeavour is a Registered Charity governed by a declaration of trust dated 29 January 1980. Its objectives are the relief of persons who are suffering from rheumatoid arthritis and related diseases and to promote and advance medical research and education concerning such disorders provided that the useful results of such research shall be published.

#### 2.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's declaration of trust, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The Charity is a Public Benefit Entity as defined by FRS 102.

The Charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 2.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 2.3 Charitable funds

Resources received are allocated to restricted funds according to the limitations specified on their use by the donors or other providers. Funds which can be used for general purposes of the Charity are treated as unrestricted.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

---

### 2 Accounting policies

(Continued)

#### 2.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacy income is recognised when the following conditions have been met: the final estate accounts have been approved, the legacy is capable of measurement and there is no reversionary interest.

Grants received for use in purchasing capital items are included as income within restricted funds and are reduced each year by an amount equivalent to depreciation of those assets.

Revenue grants are included as income on a receivable basis.

Income from drug trials is recognised only when it is certain that payment will be received and can be measured accurately.

#### 2.5 Resources expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

#### 2.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

|                       |                         |
|-----------------------|-------------------------|
| Fixtures and fittings | 15% straight line basis |
|-----------------------|-------------------------|

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

#### 2.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

#### 2.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

---

### 2 Accounting policies

(Continued)

#### 2.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

### 3 Donations and legacies

|                     | <b>Unrestricted<br/>funds</b> | Unrestricted<br>funds |
|---------------------|-------------------------------|-----------------------|
|                     | <b>2024</b>                   | 2023                  |
|                     | £                             | £                     |
| Donations and gifts | 1,694                         | 3,808                 |
| Legacies receivable | -                             | 176,859               |
|                     | <u>1,694</u>                  | <u>180,667</u>        |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

---

### 4 Charitable activities

|                    | 2024<br>£     | 2023<br>£     |
|--------------------|---------------|---------------|
| Grants             | 55,097        | 54,901        |
| Drug trial income  | 30,692        | 37,096        |
|                    | <u>85,789</u> | <u>91,997</u> |
| Analysis by fund   |               |               |
| Unrestricted funds | 30,692        | 37,096        |
| Restricted funds   | 55,097        | 54,901        |
|                    | <u>85,789</u> | <u>91,997</u> |

### 5 Investment income

|               | Unrestricted<br>funds<br>2024<br>£ | Unrestricted<br>funds<br>2023<br>£ |
|---------------|------------------------------------|------------------------------------|
| COIF          | 27,865                             | 22,044                             |
| Bank interest | 2,495                              | 215                                |
|               | <u>30,360</u>                      | <u>22,259</u>                      |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

### 6 Expenditure on charitable activities

|   | <b>Charitable<br/>activities<br/>2024<br/>£</b> | <b>Charitable<br/>activities<br/>2023<br/>£</b> |
|---|---|---|
| <b>Direct costs</b>                                       |   |   |
| Staff costs   | 213,865   | 174,233   |
| Depreciation and impairment                               | 2,112   | 675   |
| Archiving   | 253   | 285   |
| Conferences and travel                                    | 1,239   | 708   |
| Drug trials   | (5,538)   | (15,775)  |
| Patient travel  | (162)   | 256   |
| Trial costs for genomic extraction                        | 16,896  | -   |
| Insurance   | 339   | 331   |
| Stationery and computer supplies                          | 586   | 2,132   |
| Sundry expenses   | 974   | 1,569   |
| Bank charges  | 124   | 125   |
| Maintenance   | 193   | -   |
| Research  | 2,421   | 317   |
| Irrecoverable VAT   | 3,950   | 741   |
|   | <u>237,252</u>                                  | <u>165,597</u>                                  |
| <b>Share of support and governance costs (see note 7)</b> |   |   |
| Support   | 23,009  | 16,305  |
| Governance  | 12,995  | 10,685  |
|   | <u>273,256</u>                                  | <u>192,587</u>                                  |
| <b>Analysis by fund</b>                                   |   |   |
| Unrestricted funds  | 240,185   | 166,909   |
| Restricted funds  | 33,071  | 25,678  |
|   | <u>273,256</u>                                  | <u>192,587</u>                                  |

### 7 Support costs allocated to activities

|                          | <b>2024<br/>£</b> | <b>2023<br/>£</b> |
|--------------------------|-------------------|-------------------|
| Staff costs              | 23,009            | 16,305            |
| Governance costs         | 12,995            | 10,685            |
|                          | <u>36,004</u>     | <u>26,990</u>     |
| <b>Analysed between:</b> |                   |                   |
| Charitable activities    | <u>36,004</u>     | <u>26,990</u>     |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

---

|          |   |                   |                   |
|----------|---|-------------------|-------------------|
| <b>8</b> | <b>Net movement in funds</b>                                    | <b>2024</b>       | <b>2023</b>       |
|          |   | <b>£</b>          | <b>£</b>          |
|          | The net movement in funds is stated after charging/(crediting): |                   |                   |
|          | Depreciation of owned tangible fixed assets                     | 2,112             | 675               |
|          |   | <u>          </u> | <u>          </u> |

### 9 Trustees

During the year, no Trustees received any remuneration (2023 - £nil), benefits in kind (2023 - £nil) or reimbursement of expenses (2023 - £nil) in relation to their role as Trustees. During the year, the charity reimbursed Cambridge University Hospitals NHS Foundation Trust for salary costs in relation to research work carried out by the following Trustees: Dr Hall £6,843 (2023 - £14,002), Dr Jordan £nil (2023 - £4,680) and Dr Jadon £nil (2023 - £11,744). During the year, no Trustees received expenses (2023 - £nil).

### 10 Gains and losses on investments

|                            | <b>Unrestricted<br/>funds<br/>2024</b> | <b>Unrestricted<br/>funds<br/>2023</b> |
|----------------------------|--|--|
|                            | <b>£</b>                               | <b>£</b>                               |
| Gains/(losses) arising on: |  |  |
| Revaluation of investments | 61,929                                 | (32,310)                               |
|                            | <u>          </u>                      | <u>          </u>                      |

### 11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

### 12 Employees

There were no employees during the year.

|   |                   |                   |
|---|-------------------|-------------------|
| <b>Employment costs</b>   | <b>2024</b>       | <b>2023</b>       |
|   | <b>£</b>          | <b>£</b>          |
| Wages and salaries recharged from Cambridge University Hospitals NHS Foundation Trust | 244,544           | 195,973           |
|   | <u>          </u> | <u>          </u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

### 13 Tangible fixed assets

|                                    | Fixtures and fittings<br>£ |
|------------------------------------|----------------------------|
| <b>Cost</b>                        |                            |
| At 1 April 2023                    | 45,319                     |
| Additions                          | 12,322                     |
|                                    | <hr/>                      |
| At 31 March 2024                   | 57,641                     |
|                                    | <hr/>                      |
| <b>Depreciation and impairment</b> |                            |
| At 1 April 2023                    | 44,711                     |
| Depreciation charged in the year   | 2,112                      |
|                                    | <hr/>                      |
| At 31 March 2024                   | 46,823                     |
|                                    | <hr/>                      |
| <b>Carrying amount</b>             |                            |
| At 31 March 2024                   | 10,818                     |
|                                    | <hr/> <hr/>                |
| At 31 March 2023                   | 608                        |
|                                    | <hr/> <hr/>                |

### 14 Fixed asset investments

|  | COIF Units<br>£ | Deposit Fund<br>- Capital<br>£ | Deposit Fund<br>- Income<br>£ | Total<br>£  |
|--|-----------------|--------------------------------|-------------------------------|-------------|
| <b>Cost or valuation</b>               |                 |                                |                               |             |
| At 1 April 2023                        | 621,211         | 7,023                          | 254,998                       | 883,232     |
| Income retained in COIF Income Account | -               | -                              | 27,865                        | 27,865      |
| Unrealised gain/ (loss)                | 61,929          | -                              | -                             | 61,929      |
| Disposals                              | -               | -                              | (100,000)                     | (100,000)   |
|  | <hr/>           | <hr/>                          | <hr/>                         | <hr/>       |
| At 31 March 2024                       | 683,140         | 7,023                          | 182,863                       | 873,026     |
|  | <hr/>           | <hr/>                          | <hr/>                         | <hr/>       |
| <b>Carrying amount</b>                 |                 |                                |                               |             |
| At 31 March 2024                       | 683,140         | 7,023                          | 182,863                       | 873,026     |
|  | <hr/> <hr/>     | <hr/> <hr/>                    | <hr/> <hr/>                   | <hr/> <hr/> |
| At 31 March 2023                       | 621,211         | 7,023                          | 254,998                       | 883,232     |
|  | <hr/> <hr/>     | <hr/> <hr/>                    | <hr/> <hr/>                   | <hr/> <hr/> |

### 15 Debtors

|   | 2024<br>£   | 2023<br>£   |
|---|-------------|-------------|
| <b>Amounts falling due within one year:</b> |             |             |
| Trade debtors                               | 136,383     | 157,524     |
| Other debtors                               | 656         | 656         |
| Prepayments and accrued income              | 9,588       | 26,867      |
|   | <hr/>       | <hr/>       |
|   | 146,627     | 185,047     |
|   | <hr/> <hr/> | <hr/> <hr/> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

### 16 Creditors: amounts falling due within one year

|                                    | 2024<br>£      | 2023<br>£      |
|------------------------------------|----------------|----------------|
| Other taxation and social security | 12,767         | 15,737         |
| Trade creditors                    | 8,318          | 11,434         |
| Other creditors                    | 503,902        | 489,846        |
| Accruals and deferred income       | 11,653         | 17,315         |
|                                    | <u>536,640</u> | <u>534,332</u> |

### 17 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

|               | At 1 April<br>2023<br>£ | Incoming<br>resources<br>£ | Resources<br>expended<br>£ | Transfers<br>£ | At 31 March<br>2024<br>£ |
|---------------|-------------------------|----------------------------|----------------------------|----------------|--------------------------|
| Classic Study | 3,350                   | -                          | -                          | -              | 3,350                    |
| XLH Study     | 26,958                  | 34,536                     | (16,175)                   | -              | 45,319                   |
| PPIE Project  | 2,000                   | -                          | -                          | -              | 2,000                    |
| BSR Funding   | 20,551                  | 20,561                     | (16,896)                   | -              | 24,216                   |
|               | <u>52,859</u>           | <u>55,097</u>              | <u>(33,071)</u>            | <u>-</u>       | <u>74,885</u>            |

#### Previous year:

|                          | At 1 April<br>2022<br>£ | Incoming<br>resources<br>£ | Resources<br>expended<br>£ | Transfers<br>£  | At 31 March<br>2023<br>£ |
|--------------------------|-------------------------|----------------------------|----------------------------|-----------------|--------------------------|
| ePROMS and ePREMS        | 48,091                  | -                          | -                          | (48,091)        | -                        |
| Spondylarthritis Academy | 20,286                  | -                          | (20,286)                   | -               | -                        |
| Classic Study            | 3,350                   | -                          | -                          | -               | 3,350                    |
| XLH Study                | -                       | 32,350                     | (5,392)                    | -               | 26,958                   |
| PPIE Project             | -                       | 2,000                      | -                          | -               | 2,000                    |
| BSR Funding              | -                       | 20,551                     | -                          | -               | 20,551                   |
|                          | <u>71,727</u>           | <u>54,901</u>              | <u>25,678</u>              | <u>(48,091)</u> | <u>52,859</u>            |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2024

#### 18 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

|                       | At 1 April<br>2023         | Incoming<br>resources         | Resources<br>expended         | Transfers        | Gains and<br>losses         | At 31 March<br>2024         |
|-----------------------|----------------------------|-------------------------------|-------------------------------|------------------|-----------------------------|-----------------------------|
|                       | £                          | £                             | £                             | £                | £                           | £                           |
| General funds         | 609,006                    | 62,746                        | (240,185)                     | -                | 61,929                      | 493,496                     |
|                       | <u>609,006</u>             | <u>62,746</u>                 | <u>(240,185)</u>              | <u>-</u>         | <u>61,929</u>               | <u>493,496</u>              |
| <b>Previous year:</b> | <b>At 1 April<br/>2022</b> | <b>Incoming<br/>resources</b> | <b>Resources<br/>expended</b> | <b>Transfers</b> | <b>Gains and<br/>losses</b> | <b>At 31 March<br/>2023</b> |
|                       | £                          | £                             | £                             | £                | £                           | £                           |
| General funds         | 520,112                    | 240,022                       | (166,909)                     | 48,091           | (32,310)                    | 609,006                     |
|                       | <u>520,112</u>             | <u>240,022</u>                | <u>(166,909)</u>              | <u>48,091</u>    | <u>(32,310)</u>             | <u>609,006</u>              |

#### 19 Analysis of net assets between funds

|   | Unrestricted<br>funds<br>2024 | Restricted<br>funds<br>2024 | Total<br>2024  |
|---|-------------------------------|-----------------------------|----------------|
|   | £                             | £                           | £              |
| <b>Fund balances at 31 March 2024 are represented by:</b> |                               |                             |                |
| Tangible assets   | 10,818                        | -                           | 10,818         |
| Investments   | 873,026                       | -                           | 873,026        |
| Current assets/(liabilities)                              | (390,298)                     | 74,885                      | (315,413)      |
|   | <u>493,546</u>                | <u>74,885</u>               | <u>568,431</u> |
|   | <u>493,546</u>                | <u>74,885</u>               | <u>568,431</u> |
|   | <u>493,546</u>                | <u>74,885</u>               | <u>568,431</u> |
|   | Unrestricted<br>funds<br>2023 | Restricted<br>funds<br>2023 | Total<br>2023  |
|   | £                             | £                           | £              |
| <b>Fund balances at 31 March 2023 are represented by:</b> |                               |                             |                |
| Tangible assets   | 608                           | -                           | 608            |
| Investments   | 883,232                       | -                           | 883,232        |
| Current assets/(liabilities)                              | (274,784)                     | 52,859                      | (221,925)      |
|   | <u>609,056</u>                | <u>52,859</u>               | <u>661,915</u> |
|   | <u>609,056</u>                | <u>52,859</u>               | <u>661,915</u> |
|   | <u>609,056</u>                | <u>52,859</u>               | <u>661,915</u> |

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR (CARE)**

England & Wales - Charity number 802862

---

# Accounts

---

Charity registration number 802862

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR  
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2023**

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## LEGAL AND ADMINISTRATIVE INFORMATION

---

|                             |   |
|-----------------------------|---|
| <b>Trustees</b>             | Professor H Gaston<br>Dr N Shenker<br>Dr F Hall<br>Professor A McCaskie<br>S Hartshorn<br>S Ramsay (Appointed 24 October 2022)<br>His Honour Christopher Hodson (Appointed 24 October 2022) |
| <b>Charity number</b>       | 802862  |
| <b>Registered office</b>    | Box 194 Unit E6<br>Addenbrookes Hospital<br>Hills Road<br>Cambridge<br>CB2 0QQ  |
| <b>Independent examiner</b> | Mrs J Boatfield ACA<br>Ensors Accountants LLP<br>Victory House<br>Vision Park<br>Histon<br>Cambridge<br>CB24 9ZR  |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## CONTENTS

---

|   | <b>Page</b> |
|---|-------------|
| Trustees' report                        | 1 - 4       |
| Statement of Trustees' responsibilities | 5           |
| Independent examiner's report           | 6           |
| Statement of financial activities       | 7           |
| Balance sheet                           | 8           |
| Notes to the financial statements       | 9 - 17      |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 MARCH 2023

---

The Trustees present their annual report and financial statements for the year ended 31 March 2023. Cambridge Arthritis Research Endeavour is abbreviated to CARE in the report below.

The financial statements have been prepared in accordance with the accounting policies set out in note 2 to the financial statements and comply with the Charity's trust deed, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

#### **Objectives and activities**

The purpose and work of CARE is primarily in the field of arthritis and relief and education concerning such conditions.

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

The Trustees believe that the Charity's research is of huge benefit to the public. The Charity was formed by a Trust Deed dated 29 January 1990. (Charity number 802862).

Since it is essentially a medical charity, it is appropriate that most of the Trustees are medical. In setting up the charity it was recognised that it was important to have a balanced mix of Trustees. The initial mix was mainly medical with a fundraiser and a lawyer.

As Trustees have resigned and replacements needed, the broad focus has been on replacing like with like, so a medical Trustee on leaving has been replaced by an incoming medical Trustee. The Board of Trustees have felt this to be in line with the original intent of the charity. In appointing Trustees, the Board has focussed on finding Trustees, who, not only have excellent credentials, but who would also be able to make a significant contribution to the work of CARE. The Trustees intend to appoint additional trustees with legal and/or financial expertise in due course.

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

#### **Achievements and performance**

CARE administrates the academic and commercial research studies conducted in the rheumatology research unit (RRU). This includes: sourcing and accepting grants and other funds to perform the research; paying salaries of the research doctors, nurses, practitioners and administrators (under the auspices of their employer, Cambridge University Hospitals NHSFT); and paying for equipment, consumables and training required to perform the research duties.

At the beginning of 2022 we were able to restart a number of research studies following the covid pandemic. The current team comprises a senior administrator, research nurse manager, four research nurses and a research nurse practitioner. CARE has also funded several research fellows (senior doctors undertaking a period of research).

The RRU team is continuing to recruit to a number of studies and has continually met the recruitment targets. Between 2022 and 2023 we successfully recruited to an interventional clinical trial of a novel biologic therapy for osteoarthritis of the knee, led by the pharmaceutical company GlaxoSmithKline (GSK). In 2023 we started recruitment to the Immune Mediated Inflammatory Disease (IMID) study, looking at patients with RA, PsA, axial spondyloarthritis, lupus (SLE), Sjogren's syndrome, systemic sclerosis, myositis and skin psoriasis. Our hope is to better understand the genetics and biology of these diseases.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

**FOR THE YEAR ENDED 31 MARCH 2023**

---

**Dr Shenker** has an interest in chronic pain syndromes and leads the clinical service for diagnosing patients with Complex Regional Pain Syndromes (CRPS) and related conditions, collaborating with other Specialist Services within Addenbrooke's Hospital. He is Chair of the CRPS-UK Network and Registry. His research interests relate to this patient cohort and he actively recruits patients for studies in basic science (Genetics, Imaging, Neurophysiological) along with an innovative rehabilitation strategy using a Virtual Environment. Parallel to this Dr Shenker is looking at patients with active Rheumatoid Arthritis due to receive anti-TNF treatment. The study will use a 7T MRI scan to look at the brain before and after the anti-TNF therapy to investigate the improvements in general wellbeing often reported in patients with this treatment.

**Dr Frances Hall** has an interest in Connective Tissue Disease (CTD) and associated Interstitial Lung Disease (ILD) and ran a trial which showed that lung volumes and quality of life improved increased after treatment with an immunosuppressant, rituximab, and this treatment is now available to these patients.

**Prof Andrew McCaskie** is Professor of orthopaedics and directs the Versus Arthritis; Tissue Engineering and Regenerative Therapies Centre, investigating the use of stem cell therapies in joint disease. His clinical interest is lower limb, particularly hip disease in young patients. He also conducts clinical trials using cell therapy trial for knee arthritis.

### **Financial review**

Fixed asset investments have increased in value during the year by £164,695 (2022 – £61,948) and generated spendable income of £22,044 (2022 - £24,440), which the Trustees consider to be satisfactory performance.

It is the policy of the Charity that unrestricted funds which have not been designated for a specific use should be maintained at a level which is adequate to meet the charity's objectives. The Charity has a reserves policy to not let these funds fall below £500K.

The results for the year are set out in the attached financial statements. At the balance sheet date the Charity had total net assets less current liabilities of £661,915 (2022 - £591,889). The Charity reserves amounted to £608,398 (2022 - £518,830).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2023

---

The Trustees have conducted their own review of the major risks to which the Charity is exposed and systems have been established to mitigate those risks. Procedures have been put in place to minimise both the external and internal risks and these procedures are periodically reviewed to ensure that they still meet the needs of the Charity.

The risks are largely defined as being financial and/or medical. Financially, the Charity has taken professional advice and its finances are handled by CCLA Investment Management Ltd with part of its cash invested in Units and part invested on term deposits. Overall the Charity is seeking to ensure that there is approximately five years of anticipated funding needs in its reserves (or such reserves as may be advised by the Charity Commission); the five years funding in reserves is an aspiration at the moment. Steps are being taken on the fund-raising front to enhance the level of reserves.

Medically, the Charity is exposed to risk in the following ways:

*1. The CARE website*

The CARE website has been reconstructed.

*2. CARE Speaker and Social Meetings*

These events bring together members of the Rheumatology Department and patients, with their relatives and friends. Venues selected are used regularly for conferences and present no unusual hazard. Several medical members of the team are present at these events, should medical attention be required.

*3. CARE involvement in scientific research and clinical trials*

All scientific research sponsored by CARE is conducted under the ethical and management policies of Cambridge University Hospitals NHS Foundation Trust (CUHNHSFT) (to whom proposals are submitted for peer review). Where CARE staff participate in clinical trials, these are normally conducted on behalf of pharmaceutical companies, or their agents, and therefore subject to the normal regulatory processes. Where CARE sponsors clinical trials directly, these are conducted under the regulations set out by CUHNHSFT, and are subject to ethical review. Insurance against adverse outcomes in any CARE-instigated clinical trial is provided through CUHNHSFT.

### **Structure, governance and management**

The Governing document of the Charity is a Declaration of Trust dated 29 January 1990.

The address of the charity is:

Box 194 Unit E6  
Addenbrookes Hospital  
Hills Road  
Cambridge  
Cambs  
CB2 0QQ

The Trustees who served during the year and up to the date of signature of the financial statements were:

Professor H Gaston

Dr N Shenker

Dr F Hall

Professor A McCaskie

Dr D Jadon

(Deceased 17 November 2023)

Dr N Jordan

(Resigned 31 July 2022)

S Hartshorn

S Ramsay

(Appointed 24 October 2022)

His Honour Christopher Hodson

(Appointed 24 October 2022)

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### *FOR THE YEAR ENDED 31 MARCH 2023*

---

Prospective and newly appointed Trustees are given a detailed understanding of the research work carried out by CARE, so that those who are invited to join are conversant with what is expected of them.

In planning for the coming year, the Trustees agree the framework in which CARE will operate and the day-to-day detail to achieve this is delegated to the staff of CARE. Should the staff wish to change the framework, then an approach is made to the Trustees to seek their authority to make the changes.

The day to day affairs of the charity are run by the Administrator.

The charity's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.

The Trustees' report was approved by the Board of Trustees.

Professor H Gaston  
**Trustee**

29 January 2024

# **CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR**

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

***FOR THE YEAR ENDED 31 MARCH 2023***

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

---

I report to the Trustees on my examination of the financial statements of Cambridge Arthritis Research Endeavour (the Charity) for the year ended 31 March 2023.

#### **Responsibilities and basis of report**

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the Charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### **Independent examiner's statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Mrs J Boatfield ACA  
Ensors Accountants LLP

Victory House  
Vision Park  
Chivers Way  
Histon  
CB24 9ZR

Dated: 30 January 2024

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

**FOR THE YEAR ENDED 31 MARCH 2023**

|                                       | Notes | Unrestricted<br>funds<br>2023<br>£ | Restricted<br>funds<br>2023<br>£ | Total<br>2023<br>£    | Unrestricted<br>funds<br>2022<br>£ | Restricted<br>funds<br>2022<br>£ | Total<br>2022<br>£    |
|---------------------------------------|-------|------------------------------------|----------------------------------|-----------------------|------------------------------------|----------------------------------|-----------------------|
| <b>Income from:</b>                   |       |                                    |                                  |                       |                                    |                                  |                       |
| Donations and legacies                | 3     | 180,667                            | -                                | 180,667               | 5,621                              | -                                | 5,621                 |
| Charitable activities                 | 4     | 37,096                             | 54,901                           | 91,997                | 29,551                             | 53,301                           | 82,852                |
| Investments                           | 5     | 22,259                             | -                                | 22,259                | 24,449                             | -                                | 24,449                |
| <b>Total income</b>                   |       | <u>240,022</u>                     | <u>54,901</u>                    | <u>294,923</u>        | <u>59,621</u>                      | <u>53,301</u>                    | <u>112,922</u>        |
| <b>Expenditure on:</b>                |       |                                    |                                  |                       |                                    |                                  |                       |
| Charitable activities                 | 6     | 166,909                            | 25,678                           | 192,587               | 191,025                            | 5,871                            | 196,896               |
| Net gains/(losses) on investments     | 10    | (32,310)                           | -                                | (32,310)              | 61,948                             | -                                | 61,948                |
| <b>Net income/(expenditure)</b>       |       | <u>40,803</u>                      | <u>29,223</u>                    | <u>70,026</u>         | <u>(69,456)</u>                    | <u>47,430</u>                    | <u>(22,026)</u>       |
| Transfers between funds               |       | 48,091                             | (48,091)                         | -                     | -                                  | -                                | -                     |
| <b>Net movement in funds</b>          |       | <u>88,894</u>                      | <u>(18,868)</u>                  | <u>70,026</u>         | <u>(69,456)</u>                    | <u>47,430</u>                    | <u>(22,026)</u>       |
| <b>Reconciliation of funds:</b>       |       |                                    |                                  |                       |                                    |                                  |                       |
| Fund balances at 1 April 2022         |       | <u>520,162</u>                     | <u>71,727</u>                    | <u>591,889</u>        | <u>589,618</u>                     | <u>24,297</u>                    | <u>613,915</u>        |
| <b>Fund balances at 31 March 2023</b> |       | <u><u>609,056</u></u>              | <u><u>52,859</u></u>             | <u><u>661,915</u></u> | <u><u>520,162</u></u>              | <u><u>71,727</u></u>             | <u><u>591,889</u></u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET

AS AT 31 MARCH 2023

|   | Notes | 2023           |                  | 2022           |                  |
|---|-------|----------------|------------------|----------------|------------------|
|   |       | £              | £                | £              | £                |
| <b>Fixed assets</b>                                   |       |                |                  |                |                  |
| Tangible assets                                       | 13    |                | 608              |                | 1,282            |
| Investments   | 14    |                | 883,232          |                | 718,537          |
|   |       |                | <u>883,840</u>   |                | <u>719,819</u>   |
| <b>Current assets</b>                                 |       |                |                  |                |                  |
| Debtors   | 15    | 185,047        |                  | 150,633        |                  |
| Cash at bank and in hand                              |       | 127,360        |                  | 95,468         |                  |
|   |       | <u>312,407</u> |                  | <u>246,101</u> |                  |
| <b>Creditors: amounts falling due within one year</b> | 16    | (534,332)      |                  | (374,031)      |                  |
| Net current liabilities                               |       |                | <u>(221,925)</u> |                | <u>(127,930)</u> |
| <b>Total assets less current liabilities</b>          |       |                | <u>661,915</u>   |                | <u>591,889</u>   |
| <b>Income funds</b>                                   |       |                |                  |                |                  |
| Restricted funds                                      | 17    |                | 52,859           |                | 71,727           |
| Unrestricted funds                                    |       |                |                  |                |                  |
| General unrestricted funds                            |       | 609,006        |                  | 520,112        |                  |
| Trustees' subscriptions                               |       | 50             |                  | 50             |                  |
|   |       | <u>609,056</u> |                  | <u>520,162</u> |                  |
|   |       |                | <u>661,915</u>   |                | <u>591,889</u>   |

The financial statements were approved by the Trustees on 29 January 2024

Professor H Gaston  
Trustee

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2023

---

### 1 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 2 Accounting policies

#### Charity information

Cambridge Arthritis Research Endeavour is a Registered Charity governed by a declaration of trust dated 29 January 1980. Its objectives are the relief of persons who are suffering from rheumatoid arthritis and related diseases and to promote and advance medical research and education concerning such disorders provided that the useful results of such research shall be published.

#### 2.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's declaration of trust, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The Charity is a Public Benefit Entity as defined by FRS 102.

The Charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 2.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 2.3 Charitable funds

Resources received are allocated to restricted funds according to the limitations specified on their use by the donors or other providers. Funds which can be used for general purposes of the Charity are treated as unrestricted.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2023

---

### 2 Accounting policies

(Continued)

#### 2.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacy income is recognised when the following conditions have been met: the final estate accounts have been approved, the legacy is capable of measurement and there is no reversionary interest.

Grants received for use in purchasing capital items are included as income within restricted funds and are reduced each year by an amount equivalent to depreciation of those assets.

Revenue grants are included as income on a receivable basis.

Income from drug trials is recognised only when it is certain that payment will be received and can be measured accurately.

#### 2.5 Resources expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

#### 2.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

|                       |                         |
|-----------------------|-------------------------|
| Fixtures and fittings | 15% straight line basis |
|-----------------------|-------------------------|

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

#### 2.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

#### 2.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

### 2 Accounting policies

(Continued)

#### 2.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

### 3 Donations and legacies

|                     | <b>Unrestricted<br/>funds</b> | Unrestricted<br>funds |
|---------------------|-------------------------------|-----------------------|
|                     | <b>2023</b>                   | 2022                  |
|                     | £                             | £                     |
| Donations and gifts | 3,808                         | 5,621                 |
| Legacies receivable | 176,859                       | -                     |
|                     | <u>180,667</u>                | <u>5,621</u>          |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

---

### 4 Charitable activities

|                    | 2023<br>£     | 2022<br>£     |
|--------------------|---------------|---------------|
| Grants             | 54,901        | 53,301        |
| Drug trial income  | 37,096        | 29,551        |
|                    | <u>91,997</u> | <u>82,852</u> |
| Analysis by fund   |               |               |
| Unrestricted funds | 37,096        | 29,551        |
| Restricted funds   | 54,901        | 53,301        |
|                    | <u>91,997</u> | <u>82,852</u> |

### 5 Investment income

|               | Unrestricted<br>funds | Unrestricted<br>funds |
|---------------|-----------------------|-----------------------|
|               | 2023<br>£             | 2022<br>£             |
| COIF          | 22,044                | 24,440                |
| Bank interest | 215                   | 9                     |
|               | <u>22,259</u>         | <u>24,449</u>         |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

### 6 Expenditure on charitable activities

|   | <b>Charitable<br/>activities<br/>2023<br/>£</b> | <b>Charitable<br/>activities<br/>2022<br/>£</b> |
|---|---|---|
| <b>Direct costs</b>                                       |   |   |
| Staff costs   | 174,233   | 205,069   |
| Depreciation and impairment                               | 675   | 872   |
| Archiving   | 285   | 262   |
| Conferences and travel                                    | 708   | -   |
| Drug trials   | (15,775)  | (34,833)  |
| Patient travel  | 256   | 300   |
| Insurance   | 331   | 300   |
| Stationery and computer supplies                          | 2,132   | 658   |
| Sundry expenses   | 2,310   | 4,370   |
| Bank charges  | 125   | 122   |
| Research  | 317   | 1,201   |
|   | <u>165,597</u>                                  | <u>178,321</u>                                  |
| <b>Share of support and governance costs (see note 7)</b> |   |   |
| Support   | 16,305  | 12,000  |
| Governance  | 10,685  | 6,575   |
|   | <u>192,587</u>                                  | <u>196,896</u>                                  |
| <b>Analysis by fund</b>                                   |   |   |
| Unrestricted funds  | 166,909   | 191,025   |
| Restricted funds  | 25,678  | 5,871   |
|   | <u>192,587</u>                                  | <u>196,896</u>                                  |

### 7 Support costs allocated to activities

|                          | <b>2023<br/>£</b> | <b>2022<br/>£</b> |
|--------------------------|-------------------|-------------------|
| Staff costs              | 16,305            | 12,000            |
| Governance costs         | 10,685            | 6,575             |
|                          | <u>26,990</u>     | <u>18,575</u>     |
| <b>Analysed between:</b> |                   |                   |
| Charitable activities    | <u>26,990</u>     | <u>18,575</u>     |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

---

### 8 Trustees

During the year, no Trustees received any remuneration (2022 - £nil), benefits in kind (2022 - £nil) or reimbursement of expenses (2022 - £nil) in relation to their role as Trustees. During the year, the charity reimbursed Cambridge University Hospitals NHS Foundation Trust for salary costs in relation to research work carried out by the following Trustees: Dr Jordan £4,680 (2022 - £13,250), Dr Jadon £11,744 (2022 - £11,084) and Dr Hall £14,002 (2022 - £13,215). During the year, no Trustees received expenses (2022 - £nil).

### 9 Grants payable

There were no grants payable in 2023 (2022 - £nil).

### 10 Gains and losses on investments

|                            | Unrestricted<br>funds<br>2023<br>£ | Unrestricted<br>funds<br>2022<br>£ |
|----------------------------|------------------------------------|------------------------------------|
| Gains/(losses) arising on: |                                    |                                    |
| Revaluation of investments | (32,310)                           | 61,948                             |

### 11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

### 12 Employees

There were no employees during the year.

| Employment costs  | 2023<br>£ | 2022<br>£ |
|---|-----------|-----------|
| Wages and salaries recharged from Cambridge University Hospitals NHS Foundation Trust | 195,973   | 221,069   |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

### 13 Tangible fixed assets

|                                    | Fixtures and fittings<br>£ |
|------------------------------------|----------------------------|
| <b>Cost</b>                        |                            |
| At 1 April 2022                    | 45,319                     |
| At 31 March 2023                   | 45,319                     |
| <b>Depreciation and impairment</b> |                            |
| At 1 April 2022                    | 44,036                     |
| Depreciation charged in the year   | 675                        |
| At 31 March 2023                   | 44,711                     |
| <b>Carrying amount</b>             |                            |
| At 31 March 2023                   | 608                        |
| At 31 March 2022                   | 1,282                      |

### 14 Fixed asset investments

|  | COIF Units<br>£ | Deposit Fund<br>- Capital<br>£ | Deposit Fund<br>- Income<br>£ | Total<br>£ |
|--|-----------------|--------------------------------|-------------------------------|------------|
| <b>Cost or valuation</b>               |                 |                                |                               |            |
| At 1 April 2022                        | 653,521         | 7,023                          | 57,993                        | 718,537    |
| Additions                              | -               | -                              | 174,961                       | 174,961    |
| Income retained in COIF Income Account | -               | -                              | 22,044                        | 22,044     |
| Unrealised gain/ (loss)                | (32,310)        | -                              | -                             | (32,310)   |
| At 31 March 2023                       | 621,211         | 7,023                          | 254,998                       | 883,232    |
| <b>Carrying amount</b>                 |                 |                                |                               |            |
| At 31 March 2023                       | 621,211         | 7,023                          | 254,998                       | 883,232    |
| At 31 March 2022                       | 653,521         | 7,023                          | 57,993                        | 718,537    |

### 15 Debtors

|   | 2023<br>£ | 2022<br>£ |
|---|-----------|-----------|
| <b>Amounts falling due within one year:</b> |           |           |
| Trade debtors                               | 157,524   | 120,071   |
| Other debtors                               | 656       | 656       |
| Prepayments and accrued income              | 26,867    | 29,906    |
|   | 185,047   | 150,633   |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

### 16 Creditors: amounts falling due within one year

|                                    | 2023<br>£      | 2022<br>£      |
|------------------------------------|----------------|----------------|
| Other taxation and social security | 15,737         | 9,152          |
| Trade creditors                    | 11,434         | 21,446         |
| Other creditors                    | 489,846        | 311,492        |
| Accruals and deferred income       | 17,315         | 31,941         |
|                                    | <u>534,332</u> | <u>374,031</u> |

### 17 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

|                          | At 1 April<br>2022<br>£          | Incoming<br>resources<br>£          | Resources<br>expended<br>£          | Transfers<br>£         | At 31 March<br>2023<br>£          |
|--------------------------|----------------------------------|-------------------------------------|-------------------------------------|------------------------|-----------------------------------|
| ePROMS and ePREMS        | 48,091                           | -                                   | -                                   | (48,091)               | -                                 |
| Spondylarthritis Academy | 20,286                           | -                                   | (20,286)                            | -                      | -                                 |
| Classic Study            | 3,350                            | -                                   | -                                   | -                      | 3,350                             |
| XLH Study                | -                                | 32,350                              | (5,392)                             | -                      | 26,958                            |
| PPIE Project             | -                                | 2,000                               | -                                   | -                      | 2,000                             |
| BSR Funding              | -                                | 20,551                              | -                                   | -                      | 20,551                            |
|                          | <u>71,727</u>                    | <u>54,901</u>                       | <u>(25,678)</u>                     | <u>(48,091)</u>        | <u>52,859</u>                     |
| <b>Previous year:</b>    | <b>At 1 April<br/>2021<br/>£</b> | <b>Incoming<br/>resources<br/>£</b> | <b>Resources<br/>expended<br/>£</b> | <b>Transfers<br/>£</b> | <b>At 31 March<br/>2022<br/>£</b> |
| ePROMS and ePREMS        | 48,091                           | -                                   | -                                   | -                      | 48,091                            |
| Spondylarthritis Academy | (23,794)                         | 44,080                              | -                                   | -                      | 20,286                            |
| Classic Study            | -                                | 3,750                               | (400)                               | -                      | 3,350                             |
| XLH Study                | -                                | 5,471                               | (5,471)                             | -                      | -                                 |
|                          | <u>24,297</u>                    | <u>53,301</u>                       | <u>(5,871)</u>                      | <u>-</u>               | <u>71,727</u>                     |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2023

#### 18 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

|                       | At 1 April<br>2022 | Incoming<br>resources | Resources<br>expended | Transfers         | Gains and<br>losses | At 31 March<br>2023 |
|-----------------------|--------------------|-----------------------|-----------------------|-------------------|---------------------|---------------------|
|                       | £                  | £                     | £                     | £                 | £                   | £                   |
| General funds         | 520,112            | 240,022               | (166,909)             | 48,091            | (32,310)            | 609,006             |
|                       | <u>          </u>  | <u>          </u>     | <u>          </u>     | <u>          </u> | <u>          </u>   | <u>          </u>   |
| <b>Previous year:</b> | <b>At 1 April</b>  | <b>Incoming</b>       | <b>Resources</b>      | <b>Transfers</b>  | <b>Gains and</b>    | <b>At 31 March</b>  |
|                       | <b>2021</b>        | <b>resources</b>      | <b>expended</b>       |                   | <b>losses</b>       | <b>2022</b>         |
|                       | £                  | £                     | £                     | £                 | £                   | £                   |
| General funds         | 589,568            | 59,621                | (191,025)             | -                 | 61,948              | 520,112             |
|                       | <u>          </u>  | <u>          </u>     | <u>          </u>     | <u>          </u> | <u>          </u>   | <u>          </u>   |

#### 19 Analysis of net assets between funds

|   | Unrestricted<br>funds<br>2023 | Restricted<br>funds<br>2023 | Total<br>2023     |
|---|-------------------------------|-----------------------------|-------------------|
|   | £                             | £                           | £                 |
| <b>Fund balances at 31 March 2023 are represented by:</b> |                               |                             |                   |
| Tangible assets   | 608                           | -                           | 608               |
| Investments   | 883,232                       | -                           | 883,232           |
| Current assets/(liabilities)                              | (274,784)                     | 52,859                      | (221,925)         |
|   | <u>          </u>             | <u>          </u>           | <u>          </u> |
|   | 609,056                       | 52,859                      | 661,915           |
|   | <u>          </u>             | <u>          </u>           | <u>          </u> |
|   | Unrestricted<br>funds<br>2022 | Restricted<br>funds<br>2022 | Total<br>2022     |
|   | £                             | £                           | £                 |
| <b>Fund balances at 31 March 2022 are represented by:</b> |                               |                             |                   |
| Tangible assets   | 1,282                         | -                           | 1,282             |
| Investments   | 718,537                       | -                           | 718,537           |
| Current assets/(liabilities)                              | (199,657)                     | 71,727                      | (127,930)         |
|   | <u>          </u>             | <u>          </u>           | <u>          </u> |
|   | 520,162                       | 71,727                      | 591,889           |
|   | <u>          </u>             | <u>          </u>           | <u>          </u> |

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR (CARE)**

England & Wales - Charity number 802862

---

# Accounts

---

Charity registration number 802862

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR  
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2022**

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## LEGAL AND ADMINISTRATIVE INFORMATION

---

|                             |   |  |
|-----------------------------|---|--|
| <b>Trustees</b>             | Professor H Gaston<br>Dr N Shenker<br>Dr F Hall<br>Professor A McCaskie<br>Dr D Jadon<br>S Hartshorn<br>S Ramsay<br>His Honour Christopher Hodson | (Appointed 22 November 2021)<br>(Appointed 24 October 2022)<br>(Appointed 24 October 2022) |
| <b>Charity number</b>       | 802862  |  |
| <b>Registered office</b>    | Box 194 Unit E6<br>Addenbrookes Hospital<br>Hills Road<br>Cambridge<br>CB2 0QQ  |  |
| <b>Independent examiner</b> | Mrs J Boatfield ACA<br>Ensors Accountants LLP<br>Victory House<br>Vision Park<br>Histon<br>Cambridge<br>CB24 9ZR                                  |  |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## CONTENTS

---

|   | <b>Page</b> |
|---|-------------|
| Trustees' report                        | 1 - 4       |
| Statement of Trustees' responsibilities | 5           |
| Independent examiner's report           | 6           |
| Statement of financial activities       | 7           |
| Balance sheet                           | 8           |
| Notes to the financial statements       | 9 - 16      |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT

### *FOR THE YEAR ENDED 31 MARCH 2022*

---

The Trustees present their annual report and financial statements for the year ended 31 March 2022. Cambridge Arthritis Research Endeavour is abbreviated to CARE in the report below.

The financial statements have been prepared in accordance with the accounting policies set out in note 2 to the financial statements and comply with the Charity's trust deed, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

#### **Objectives and activities**

The purpose and work of CARE is primarily in the field of arthritis and relief and education concerning such conditions.

The Trustees have referred to the Charity Commission's general guidance on Public Benefit when reviewing our aims and objectives and in planning the Charity's future activities and believe that the activities of the Charity clearly demonstrate a direct public benefit.

The Trustees believe that the Charity's research is of huge benefit to the public. The Charity was formed by a Trust Deed dated 29 January 1990. (Charity number 802862).

Since it is essentially a medical charity, it is appropriate that most of the Trustees are medical. In setting up the charity it was recognised that it was important to have a balanced mix of Trustees. The initial mix was mainly medical with a fundraiser and a lawyer.

As Trustees have resigned and replacements needed, the broad focus has been on replacing like with like, so a medical Trustee on leaving has been replaced by an incoming medical Trustee. The Board of Trustees have felt this to be in line with the original intent of the charity. In appointing Trustees, the Board has focussed on finding Trustees, who, not only have excellent credentials, but who would also be able to make a significant contribution to the work of CARE. The Trustees intend to appoint additional trustees with legal and/or financial expertise in due course.

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2022

---

#### Achievements and performance

CARE administrates the academic and commercial research studies conducted in the rheumatology research unit (RRU). This includes: sourcing and accepting grants and other funds to perform the research; pay salaries of the research doctors, nurses, practitioners and administrators (under the auspices of their employer, Cambridge University Hospitals NHSFT); and pay for equipment, consumables and training required to perform the research duties.

Rheumatology related research mostly stopped or was temporarily put on hold during the Covid pandemic due to the limitations imposed with the closure of clinics and reduced face2face contact. A number of studies were unable to restart due to priority being given to COVID related studies. Observational studies which could be conducted remotely continued, including collecting data for The British Society for Rheumatology Biologics Registers. At the beginning of 2022 many of our studies were restarted. The current team comprises a senior administrator, research nurse manager, four research nurses and a research nurse practitioner. CARE has also funded several research fellows (senior doctors undertaking a period of research).

We have been involved in investigator driven clinical research, collaborating with drug companies to investigate if existing licenced drugs could be used for Covid-19. CARE has been involved in trials looking at which treatment would work best for a particular patient, whether a combination of treatments, or perhaps a sequence of different agents.

Following the pandemic research was reopened at Cambridge University Hospitals NHSFT with priority given to studies looking into Covid-19. Therefore existing and new studies are commencing steadily, with 15 clinical studies active and more due to open in the forthcoming year.

**Dr Deepak Jadon** is a consultant rheumatologist and Director of the Rheumatology Research Unit (RRU) at Addenbrooke's Hospital. His clinical and research interests relate to psoriatic arthritis (PsA), ankylosing spondylitis (AS), rheumatoid arthritis (RA) and osteoarthritis (OA).

The RRU team is recruiting to the: **MONITOR-PsA** study which is an inception (from first diagnosis) cohort study of patients with PsA running for 5 years and recruiting 500 patients across Cambridge, Oxford and Bath and the nested clinical trial, **SPEED-PsA** study. There will be a number of new studies opening mid to late 2022.

**Dr Natasha Jordan** has an interest in studies in Autoimmune Connective Tissues Diseases (CTD). Dr Jordan's studies continue where possible with some remaining on hold following Dr Jordan's departure from Cambridge University Hospitals NHSFT.

**Dr Shenker** is a consultant rheumatologist and has an interest in chronic pain syndromes and leads the clinical service for diagnosing patients with Complex Regional Pain Syndromes and related conditions, collaborating with other Specialist Services within Addenbrooke's Hospital. He is Chair of the CRPS-UK Network and Registry. His research interests relate to this patient cohort and he actively recruits patients for studies in basic science (Genetics, Imaging, Neurophysiological) along with an innovative rehabilitation strategy using a Virtual Environment.

**Dr Frances Hall** continued with the TACTIC-R study looking at severe disease manifestations of Covid-19 which were mainly inflammatory. The trial raised the prospect that immunosuppression licenced for use in other diseases, might be an effective therapy for efficacy in Covid-19. Enrolment into TACTIC—R started on 8<sup>th</sup> May 2020 and completed May 2021. A manuscript will be published in The Lancet.

Dr Hall also has an interest in Connective Tissue Disease (CTD) and associated Interstitial Lung Disease (ILD) and ran a trial which showed that lung volumes increased and quality of life improved in both groups of patients after treatment with Rituximab, which has led to a funded treatment pathway to enable use of rituximab in patient with CTD and ILD.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

**FOR THE YEAR ENDED 31 MARCH 2022**

---

**Prof Andrew McCaskie** was appointed Professor of Orthopaedic Surgery in 2013 and became Head of the Department of Surgery in 2017. In 2011 he led the successful bid to establish the Arthritis Research UK Tissue Engineering Centre, and became its Director. The Centre brings together many institutions across the UK in addition to clinicians, engineers and biologists from research and clinical groups to develop regenerative therapies for people with Osteoarthritis. The centre was subsequently renamed; Versus Arthritis; Tissue Engineering and Regenerative Therapies Centre. Professor McCaskie led the Smart Step programme as part of Stage II UK Regenerative Medicine Platform and is a co-investigator in the UK Regenerative Medicine Platform Hub; Engineered cell environment. His clinical interest is lower limb, particularly hip disease in young patients and he aims to link research to the clinic, for example clinical trials (cell therapy trial for knee arthritis). He is Director of the Academic Foundation Programme in Cambridge, establishing the transplant and regeneration theme. He Chairs the Cell Therapy Oversight Committee and more recently became co-lead for the NIHR MSK TRC Musculoskeletal conditions theme.

### **Financial review**

Fixed asset investments have increased in value during the year by £61,948 (2021 – £138,161) and generated spendable income of £24,440 (2021 - £23,735), which the Trustees consider to be satisfactory performance.

It is the policy of the Charity that unrestricted funds which have not been designated for a specific use should be maintained at a level which is adequate to meet the charity's objectives. The Charity has a reserves policy to not let these funds fall below £500K.

The results for the year are set out in the attached financial statements. At the balance sheet date the Charity had total net assets less current liabilities of £591,889 (2021 - £613,915). The Charity reserves amounted to £518,830 (2021 - £587,996).

The Trustees have conducted their own review of the major risks to which the Charity is exposed and systems have been established to mitigate those risks. Procedures have been put in place to minimise both the external and internal risks and these procedures are periodically reviewed to ensure that they still meet the needs of the Charity.

The risks are largely defined as being financial and/or medical. Financially, the Charity has taken professional advice and its finances are handled by CCLA Investment Management Ltd with part of its cash invested in Units and part invested on term deposits. Overall the Charity is seeking to ensure that there is approximately five years of anticipated funding needs in its reserves (or such reserves as may be advised by the Charity Commission); the five years funding in reserves is an aspiration at the moment. Steps are being taken on the fund-raising front to enhance the level of reserves.

Medically, the Charity is exposed to risk in the following ways:

#### *1. The CARE website*

The CARE website has been reconstructed.

#### *2. CARE Speaker and Social Meetings*

These events bring together members of the Rheumatology Department and patients, with their relatives and friends. Venues selected are used regularly for conferences and present no unusual hazard. Several medical members of the team are present at these events, should medical attention be required.

#### *3. CARE involvement in scientific research and clinical trials*

All scientific research sponsored by CARE is conducted under the ethical and management policies of Cambridge University Hospitals NHS Foundation Trust (CUHNHSFT) (to whom proposals are submitted for peer review). Where CARE staff participate in clinical trials, these are normally conducted on behalf of pharmaceutical companies, or their agents, and therefore subject to the normal regulatory processes. Where CARE sponsors clinical trials directly, these are conducted under the regulations set out by CUHNHSFT, and are subject to ethical review. Insurance against adverse outcomes in any CARE-instigated clinical trial is provided through CUHNHSFT.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2022

---

#### Structure, governance and management

The Governing document of the Charity is a Declaration of Trust dated 29 January 1990.

The address of the charity is:

Box 194 Unit E6  
Addenbrookes Hospital  
Hills Road  
Cambridge  
Cambs  
CB2 0QQ

The Trustees who served during the year and up to the date of signature of the financial statements were:

Professor H Gaston

Dr N Shenker

Dr F Hall

Professor A McCaskie

Dr D Jadon

Dr N Jordan

(Resigned 31 July 2022)

S Hartshorn

(Appointed 22 November 2021)

S Ramsay

(Appointed 24 October 2022)

His Honour Christopher Hodson

(Appointed 24 October 2022)

Prospective and newly appointed Trustees are given a detailed understanding of the research work carried out by CARE, so that those who are invited to join are conversant with what is expected of them.

In planning for the coming year, the Trustees agree the framework in which CARE will operate and the day-to-day detail to achieve this is delegated to the staff of CARE. Should the staff wish to change the framework, then an approach is made to the Trustees to seek their authority to make the changes.

The day to day affairs of the charity are run by the Administrator.

The charity's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.

The Trustees' report was approved by the Board of Trustees.

Professor H Gaston

**Trustee**

3 January 2023

# **CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR**

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

***FOR THE YEAR ENDED 31 MARCH 2022***

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

---

I report to the Trustees on my examination of the financial statements of Cambridge Arthritis Research Endeavour (the Charity) for the year ended 31 March 2022.

#### **Responsibilities and basis of report**

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the Charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### **Independent examiner's statement**

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Mrs J Boatfield ACA  
Ensors Accountants LLP

Victory House  
Vision Park  
Chivers Way  
Histon  
CB24 9ZR

Dated: 4 January 2023

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2022

|                                       | Notes | Unrestricted funds<br>2022<br>£ | Restricted funds<br>2022<br>£ | Total Unrestricted funds<br>2022<br>£ | Restricted funds<br>2021<br>£ | Total<br>2021<br>£    |
|---------------------------------------|-------|---------------------------------|-------------------------------|---------------------------------------|-------------------------------|-----------------------|
| <b>Income from:</b>                   |       |                                 |                               |                                       |                               |                       |
| Donations and legacies                | 3     | 5,621                           | -                             | 5,621                                 | 3,245                         | 3,245                 |
| Charitable activities                 | 4     | 29,551                          | 53,301                        | 82,852                                | 49,435                        | 49,435                |
| Investment income                     | 5     | 24,449                          | -                             | 24,449                                | 23,837                        | 23,837                |
| <b>Total income</b>                   |       | <u>59,621</u>                   | <u>53,301</u>                 | <u>112,922</u>                        | <u>-</u>                      | <u>76,517</u>         |
| <b>Expenditure on:</b>                |       |                                 |                               |                                       |                               |                       |
| Charitable activities                 | 6     | 191,025                         | 5,871                         | 196,896                               | 33,554                        | 244,032               |
| Net gains/(losses) on investments     | 10    | 61,948                          | -                             | 61,948                                | -                             | 138,161               |
| <b>Net movement in funds</b>          |       | <u>(69,456)</u>                 | <u>47,430</u>                 | <u>(22,026)</u>                       | <u>4,200</u>                  | <u>(29,354)</u>       |
| Fund balances at 1 April 2021         |       | <u>589,618</u>                  | <u>24,297</u>                 | <u>613,915</u>                        | <u>57,851</u>                 | <u>643,269</u>        |
| <b>Fund balances at 31 March 2022</b> |       | <u><u>520,162</u></u>           | <u><u>71,727</u></u>          | <u><u>591,889</u></u>                 | <u><u>24,297</u></u>          | <u><u>613,915</u></u> |

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET

AS AT 31 MARCH 2022

|   | Notes | 2022           |                  | 2021           |                  |
|---|-------|----------------|------------------|----------------|------------------|
|   |       | £              | £                | £              | £                |
| <b>Fixed assets</b>                                   |       |                |                  |                |                  |
| Tangible assets                                       | 12    |                | 1,282            |                | 1,572            |
| Investments   | 13    |                | 718,537          |                | 961,148          |
|   |       |                | <u>719,819</u>   |                | <u>962,720</u>   |
| <b>Current assets</b>                                 |       |                |                  |                |                  |
| Debtors   | 14    | 150,633        |                  | 73,891         |                  |
| Cash at bank and in hand                              |       | 95,468         |                  | 69,831         |                  |
|   |       | <u>246,101</u> |                  | <u>143,722</u> |                  |
| <b>Creditors: amounts falling due within one year</b> | 15    | (374,031)      |                  | (492,527)      |                  |
| Net current liabilities                               |       |                | <u>(127,930)</u> |                | <u>(348,805)</u> |
| <b>Total assets less current liabilities</b>          |       |                | <u>591,889</u>   |                | <u>613,915</u>   |
| <b>Income funds</b>                                   |       |                |                  |                |                  |
| Restricted funds                                      | 16    |                | 71,727           |                | 24,297           |
| Unrestricted funds                                    |       |                |                  |                |                  |
| General unrestricted funds                            |       | 520,112        |                  | 589,568        |                  |
| Trustees' subscriptions                               |       | 50             |                  | 50             |                  |
|   |       | <u>520,162</u> |                  | <u>589,618</u> |                  |
|   |       |                | <u>591,889</u>   |                | <u>613,915</u>   |

The financial statements were approved by the Trustees on 3 January 2023

Professor H Gaston  
Trustee

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2022

---

### 1 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 2 Accounting policies

#### Charity information

Cambridge Arthritis Research Endeavour is a Registered Charity governed by a declaration of trust dated 29 January 1980. Its objectives are the relief of persons who are suffering from rheumatoid arthritis and related diseases and to promote and advance medical research and education concerning such disorders provided that the useful results of such research shall be published.

#### 2.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's declaration of trust, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The Charity is a Public Benefit Entity as defined by FRS 102.

The Charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 2.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 2.3 Charitable funds

Resources received are allocated to restricted funds according to the limitations specified on their use by the donors or other providers. Funds which can be used for general purposes of the Charity are treated as unrestricted.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

---

### 2 Accounting policies

(Continued)

#### 2.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacy income is recognised when the following conditions have been met: the final estate accounts have been approved, the legacy is capable of measurement and there is no reversionary interest.

Grants received for use in purchasing capital items are included as income within restricted funds and are reduced each year by an amount equivalent to depreciation of those assets.

Revenue grants are included as income on a receivable basis.

Income from drug trials is recognised only when it is certain that payment will be received and can be measured accurately.

#### 2.5 Resources expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

#### 2.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

|                       |                         |
|-----------------------|-------------------------|
| Fixtures and fittings | 15% straight line basis |
|-----------------------|-------------------------|

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

#### 2.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

#### 2.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

---

### 2 Accounting policies

(Continued)

#### 2.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

### 3 Donations and legacies

|                     | <b>Unrestricted<br/>funds</b> | Unrestricted<br>funds |
|---------------------|-------------------------------|-----------------------|
|                     | <b>2022</b>                   | 2021                  |
|                     | <b>£</b>                      | £                     |
| Donations and gifts | 5,621                         | 3,245                 |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

---

### 4 Charitable activities

|                    | 2022<br>£     | 2021<br>£     |
|--------------------|---------------|---------------|
| Grants             | 53,301        | -             |
| Drug trial income  | 29,551        | 49,435        |
|                    | <u>82,852</u> | <u>49,435</u> |
| Analysis by fund   |               |               |
| Unrestricted funds | 29,551        | 49,435        |
| Restricted funds   | 53,301        | -             |
|                    | <u>82,852</u> | <u>49,435</u> |

### 5 Investment income

|               | Unrestricted<br>funds<br>2022<br>£ | Unrestricted<br>funds<br>2021<br>£ |
|---------------|------------------------------------|------------------------------------|
| COIF          | 24,440                             | 23,735                             |
| Bank interest | 9                                  | 102                                |
|               | <u>24,449</u>                      | <u>23,837</u>                      |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

### 6 Charitable activities

|  | 2022<br>£      | 2021<br>£      |
|--|----------------|----------------|
| Staff costs                            | 205,069        | 235,175        |
| Depreciation and impairment            | 872            | 784            |
| Archiving                              | 262            | 261            |
| Conferences and travel                 | -              | 313            |
| Drug trials                            | (34,833)       | (19,151)       |
| Patient travel                         | 300            | 101            |
| Insurance                              | 300            | 284            |
| Stationery and computer supplies       | 658            | 1,373          |
| Sundry expenses                        | 4,370          | 7,575          |
| Bank charges                           | 122            | 108            |
| Research                               | 1,201          | -              |
|  | <u>178,321</u> | <u>226,823</u> |
| Share of support costs (see note 7)    | 12,000         | 11,518         |
| Share of governance costs (see note 7) | 6,575          | 5,691          |
|  | <u>196,896</u> | <u>244,032</u> |
| <b>Analysis by fund</b>                |                |                |
| Unrestricted funds                     | 191,025        | 210,478        |
| Restricted funds                       | 5,871          | 33,554         |
|  | <u>196,896</u> | <u>244,032</u> |

### 7 Support costs

|  | Support<br>costs<br>£ | Governance<br>costs<br>£ | 2022<br>£     | Support<br>costs<br>£ | Governance<br>costs<br>£ | 2021<br>£     |
|--|-----------------------|--------------------------|---------------|-----------------------|--------------------------|---------------|
| Staff costs                            | 12,000                | -                        | 12,000        | 11,518                | -                        | 11,518        |
| Independent examiner's fees            | -                     | 2,575                    | 2,575         | -                     | 1,852                    | 1,852         |
| Recharged employment costs             | -                     | 4,000                    | 4,000         | -                     | 3,839                    | 3,839         |
|  | <u>12,000</u>         | <u>6,575</u>             | <u>18,575</u> | <u>11,518</u>         | <u>5,691</u>             | <u>17,209</u> |
| Analysed between Charitable activities | <u>12,000</u>         | <u>6,575</u>             | <u>18,575</u> | <u>11,518</u>         | <u>5,691</u>             | <u>17,209</u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

---

### 8 Grants payable

There were no grants payable in 2022 (2021 - £nil).

### 9 Trustees

During the year, no Trustees received any remuneration (2021 - £nil), benefits in kind (2021 - £nil) or reimbursement of expenses (2021 - £nil) in relation to their role as Trustees. During the year, the charity reimbursed Cambridge University Hospitals NHS Foundation Trust for salary costs in relation to research work carried out by the following Trustees: Dr Jordan £13,250 (2021 - £12,864), Dr Jadon £11,084 (2021 - £10,761) and Dr Hall £13,215 (2021 - £12,830). During the year, no Trustees received expenses (2021 - £nil).

### 10 Net gains/(losses) on investments

|                            | <b>Unrestricted<br/>funds</b> | Unrestricted<br>funds |
|----------------------------|-------------------------------|-----------------------|
|                            | <b>2022</b>                   | 2021                  |
|                            | <b>£</b>                      | <b>£</b>              |
| Revaluation of investments | 61,948                        | 138,161               |
|                            | <u>61,948</u>                 | <u>138,161</u>        |

### 11 Employees

There were no employees during the year.

| <b>Employment costs</b>   | <b>2022</b>    | <b>2021</b>    |
|---|----------------|----------------|
|   | <b>£</b>       | <b>£</b>       |
| Wages and salaries recharged from Cambridge University Hospitals NHS Foundation Trust | 221,069        | 250,532        |
|   | <u>221,069</u> | <u>250,532</u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

### 12 Tangible fixed assets

|                                    | Fixtures and fittings<br>£ |
|------------------------------------|----------------------------|
| <b>Cost</b>                        |                            |
| At 1 April 2021                    | 44,736                     |
| Additions                          | 583                        |
|                                    | <hr/>                      |
| At 31 March 2022                   | 45,319                     |
|                                    | <hr/>                      |
| <b>Depreciation and impairment</b> |                            |
| At 1 April 2021                    | 43,165                     |
| Depreciation charged in the year   | 872                        |
|                                    | <hr/>                      |
| At 31 March 2022                   | 44,037                     |
|                                    | <hr/>                      |
| <b>Carrying amount</b>             |                            |
| At 31 March 2022                   | 1,282                      |
|                                    | <hr/> <hr/>                |
| At 31 March 2021                   | 1,572                      |
|                                    | <hr/> <hr/>                |

### 13 Fixed asset investments

|  | COIF Units<br>£ | Deposit Fund<br>- Capital<br>£ | Deposit Fund<br>- Income<br>£ | Total<br>£  |
|--|-----------------|--------------------------------|-------------------------------|-------------|
| <b>Cost or valuation</b>               |                 |                                |                               |             |
| At 1 April 2021                        | 805,572         | 7,023                          | 148,553                       | 961,148     |
| Income retained in COIF Income Account | -               | -                              | 24,440                        | 24,440      |
| Unrealised gain                        | 61,949          | -                              | -                             | 61,949      |
| Disposals                              | (214,000)       | -                              | (115,000)                     | (329,000)   |
|  | <hr/>           | <hr/>                          | <hr/>                         | <hr/>       |
| At 31 March 2022                       | 653,521         | 7,023                          | 57,993                        | 718,537     |
|  | <hr/>           | <hr/>                          | <hr/>                         | <hr/>       |
| <b>Carrying amount</b>                 |                 |                                |                               |             |
| At 31 March 2022                       | 653,521         | 7,023                          | 57,993                        | 718,537     |
|  | <hr/> <hr/>     | <hr/> <hr/>                    | <hr/> <hr/>                   | <hr/> <hr/> |
| At 31 March 2021                       | 805,572         | 7,023                          | 148,553                       | 961,148     |
|  | <hr/> <hr/>     | <hr/> <hr/>                    | <hr/> <hr/>                   | <hr/> <hr/> |

### 14 Debtors

|   | 2022<br>£   | 2021<br>£   |
|---|-------------|-------------|
| <b>Amounts falling due within one year:</b> |             |             |
| Trade debtors                               | 120,071     | 52,983      |
| Other debtors                               | 656         | 656         |
| Prepayments and accrued income              | 29,906      | 20,252      |
|   | <hr/>       | <hr/>       |
|   | 150,633     | 73,891      |
|   | <hr/> <hr/> | <hr/> <hr/> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2022

#### 15 Creditors: amounts falling due within one year

|                                    | 2022<br>£      | 2021<br>£      |
|------------------------------------|----------------|----------------|
| Other taxation and social security | 9,152          | 2,060          |
| Trade creditors                    | 21,446         | 21,798         |
| Other creditors                    | 311,492        | 402,076        |
| Accruals and deferred income       | 31,941         | 66,593         |
|                                    | <u>374,031</u> | <u>492,527</u> |

#### 16 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

|                          | Balance at<br>1 April 2020<br>£ | Resources<br>expended<br>£ | Balance at<br>1 April 2021<br>£ | Movement in funds          |                            | Balance at<br>31 March<br>2022<br>£ |
|--------------------------|---------------------------------|----------------------------|---------------------------------|----------------------------|----------------------------|-------------------------------------|
|                          |                                 |                            |                                 | Incoming<br>resources<br>£ | Resources<br>expended<br>£ |                                     |
| ePROMS and ePREMS        | 48,091                          | -                          | 48,091                          | -                          | -                          | 48,091                              |
| Spondylarthritis Academy | 9,760                           | (33,554)                   | (23,794)                        | 44,080                     | -                          | 20,286                              |
| Classic Study            | -                               | -                          | -                               | 3,750                      | (400)                      | 3,350                               |
| XLH Study                | -                               | -                          | -                               | 5,471                      | (5,471)                    | -                                   |
|                          | <u>57,851</u>                   | <u>(33,554)</u>            | <u>24,297</u>                   | <u>53,301</u>              | <u>(5,871)</u>             | <u>71,727</u>                       |

#### 17 Analysis of net assets between funds

|  | Unrestricted<br>funds<br>2022<br>£ | Restricted<br>funds<br>2022<br>£ | Total<br>2022<br>£ | Unrestricted<br>funds<br>2021<br>£ | Restricted<br>funds<br>2021<br>£ | Total<br>2021<br>£ |
|--|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| Fund balances at 31<br>March 2022 are<br>represented by: |                                    |                                  |                    |                                    |                                  |                    |
| Tangible assets  | 1,282                              | -                                | 1,282              | 1,572                              | -                                | 1,572              |
| Investments  | 718,537                            | -                                | 718,537            | 961,148                            | -                                | 961,148            |
| Current assets/(liabilities)                             | (199,657)                          | 71,727                           | (127,930)          | (373,102)                          | 24,297                           | (348,805)          |
|  | <u>520,162</u>                     | <u>71,727</u>                    | <u>591,889</u>     | <u>589,618</u>                     | <u>24,297</u>                    | <u>613,915</u>     |

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR (CARE)**

England & Wales - Charity number 802862

---

# Accounts

---

Charity Registration No. 802862

**CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR  
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021**

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## LEGAL AND ADMINISTRATIVE INFORMATION

---

|                             |  |
|-----------------------------|--|
| <b>Trustees</b>             | Professor H Gaston<br>Dr N Shenker<br>Dr F Hall<br>Professor A McCaskie<br>Dr D Jadon<br>Dr N Jordan             |
| <b>Charity number</b>       | 802862   |
| <b>Registered office</b>    | Box 194 Unit E6<br>Addenbrookes Hospital<br>Hills Road<br>Cambridge<br>Cambridgeshire<br>CB2 0QQ                 |
| <b>Independent examiner</b> | Mrs J Boatfield ACA<br>Ensors Accountants LLP<br>Victory House<br>Vision Park<br>Histon<br>Cambridge<br>CB24 9ZR |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## CONTENTS

---

|   | <b>Page</b> |
|---|-------------|
| Trustees' report                        | 1 - 4       |
| Statement of Trustees' responsibilities | 5           |
| Independent examiner's report           | 6           |
| Statement of financial activities       | 7           |
| Balance sheet                           | 8           |
| Notes to the financial statements       | 9 - 17      |

---

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT

### *FOR THE YEAR ENDED 31 MARCH 2021*

---

The Trustees present their annual report and financial statements for the year ended 31 March 2021. Cambridge Arthritis Research Endeavour is abbreviated to CARE in the report below.

The financial statements have been prepared in accordance with the accounting policies set out in note 2 to the financial statements and comply with the Charity's trust deed, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016)

#### **Objectives and activities**

The purpose and work of CARE is primarily in the field of arthritis and relief and education concerning such conditions.

The Trustees have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers.

The Trustees believe that the Charity's research is of huge benefit to the public. The Charity was formed by a Trust Deed dated 29 January 1990. (Charity number 802862).

Since it is essentially a medical charity, it is appropriate that most of the Trustees are medical. In setting up the charity it was recognised that it was important to have a balanced mix of Trustees. The initial mix was mainly medical with a fundraiser and a lawyer.

As Trustees have resigned and replacements needed, the broad focus has been on replacing like with like, so a medical Trustee on leaving has been replaced by an incoming medical Trustee. The Board of Trustees have felt this to be in line with the original intent of the charity. In appointing Trustees, the Board has focussed on finding Trustees, who, not only have excellent credentials, but who would also be able to make a significant contribution to the work of CARE. The Trustees intend to appoint additional trustees with legal and/or financial expertise in due course.

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

**FOR THE YEAR ENDED 31 MARCH 2021**

---

### **Achievements and performance**

CARE administrates the academic and commercial research studies conducted in the rheumatology research unit (RRU). This includes: accepting grants and other funds to perform the research; pay salaries of the research doctors, nurses, practitioners and administrators (under the auspices of their employer, Cambridge University Hospitals NHSFT); and pay for equipment, consumables and training required to perform the research duties.

The charity has continued to support research activities across a wide field of topics that are important in rheumatology. Although the COVID-19 pandemic imposed limitations on our ongoing trials, with many temporarily put on hold, we have set up eight new trials, and restarted a number of projects collecting data for The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS), **Psoriatic Arthritis Register (BSRBR-PsA)** and Rheumatoid Arthritis (BSRBR-RA). In addition, rheumatologists have used their expertise in clinical trials and the use of “biological” treatments. The pandemic highlighted the crucial importance of rapid and well-organized research trials to discover useful treatments for a novel disease and to understand it better. The Tactic-R trial, led by Dr Frances Hall and supported by our research nurses, and enrolment to the trial started in May 2020. Patients were recruited across 22 sites in the UK. The trial looked at the prospect of using current licenced immunosuppression agents as an effective therapy against Covid-19. The charity is committed to using the knowledge and experience gained throughout the pandemic to continue to investigate rheumatic diseases and their treatment with the urgency and efficiency as needed.

**Dr Deepak Jadon** is a consultant rheumatologist and Director of the Rheumatology Research Unit (RRU) at Addenbrooke's Hospital. His clinical and research interests relate to inflammatory arthritides such as psoriatic arthritis (PsA), ankylosing spondylitis (AS) and rheumatoid arthritis (RA).

We currently have approaching 20 active clinical studies and several due to start over the coming year. We have a balanced portfolio of academic and non-academic (often clinical trials of new medications) research. The team comprises of a senior administrator, a research nurse manager, four research nurses, a research practitioner and several research fellows.

**Dr Natasha Jordan** has an interest in studies in Autoimmune Connective Tissue Diseases (CTD). The clinical trial studies recently opened include the SLEek study, an international multicentre trial investigating the safety and efficacy of ABBV-105 and Upadacitinib in active SLE patients. In conjunction with the University of Leeds the GCA Consortium aims to establish a database which will permit clinical characterisation of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) with a view to developing a better understanding of these diseases. The research team will carry out genetic studies investigating the contribution of relevant genes to the susceptibility to GCA/PMR and the risk of complications and response to therapy.

In addition the United Kingdom primary Sjögren's syndrome registry is a study aiming to establish a cohort of well-characterised primary Sjögren's syndrome (pSS) patients and matched healthy controls, together with samples of DNA, RNA, serum and immune cells in order to facilitate clinical trials, genetic and epidemiological studies in this disease area.

**Dr Nicholas Shenker** continues to be an active member of CamPAIN contributing to the research studies collaborating with various scientists across the Cambridge biomedical campus. Participants with Complex Regional Pain Syndromes have contributed to several studies including having their genetic coded sequenced (exome sequencing) and their pain responses studies with EEG. This work is in collaboration with a group in Switzerland and a technology firm that provides the headsets to study the electrical activity from their brains (EEG) to wear at home, recording what the brain 'looks like' when the person experiences pain.

**Dr Frances Hall** has a number of studies which have now closed and have been analysed, the results embargoed pending publication. Due to the Covid-19 pandemic other studies were put on hold due to managers and statisticians have been fully-engaged with Covid-related studies. As a result of the pandemic a '**multi-Arm Therapeutic study in pre-Icu patients admitted with Covid -19 – Repurposed Drugs (TACTIC-R)**' was opened. TACTIC-R is a platform clinical trial designed to test immunomodulatory agents, licenced for use in other diseases, for efficacy in Covid-19. Enrolment into TACTIC—R spanned 12 months with recruitment across 22 sites in the United Kingdom.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

---

**Prof Andrew McCaskie** became Head of the Department of Surgery in 2017. He established and became Director of the Arthritis Research UK Tissue Engineering Centre. The Centre brings together many institutions across the UK in addition to clinicians, engineers and biologists from research and clinical groups to develop regenerative therapies for people with Osteoarthritis. The centre was subsequently renamed; Versus Arthritis; Tissue Engineering and Regenerative Therapies Centre. Professor McCaskie led the Smart Step programme as part of Stage II UK Regenerative Medicine Platform and is a co-investigator in the recently established UK Regenerative Medicine Platform Hub; Engineered cell environment. His clinical interest is lower limb, particularly hip disease in young patients and he aims to link research to the clinic, for example clinical trials (cell therapy trial for knee arthritis). He is one of the three editors of Bailey and Love's Short Practice of Surgery 27th Edition and is the Director of the Academic Foundation Programme in Cambridge, establishing the transplant and regeneration theme. He Chairs the Cell Therapy Oversight Committee and represents Addenbrooke's in the Midlands and Wales Advanced Therapy Treatment Centre.

#### **Financial review**

Fixed asset investments have increased in value during the year by £138,161 (2020 – decrease of £23,377) and generated spendable income of £23,735 (2020 - £24,196), which the Trustees consider to be satisfactory performance.

It is the policy of the Charity that unrestricted funds which have not been designated for a specific use should be maintained at a level which is adequate to meet the charity's objectives.

The results for the year are set out in the attached financial statements. At the balance sheet date the Charity had total net assets less current liabilities of £613,915 (2020 - £643,269). The Charity reserves amounted to £587,996 (2020 - £583,012).

The Trustees have conducted their own review of the major risks to which the Charity is exposed and systems have been established to mitigate those risks. Procedures have been put in place to minimise both the external and internal risks and these procedures are periodically reviewed to ensure that they still meet the needs of the Charity.

The risks are largely defined as being financial and/or medical. Financially, the Charity has taken professional advice and its finances are handled by CCLA Investment Management Ltd with part of its cash invested in Units and part invested on term deposits. Overall the Charity is seeking to ensure that there is approximately five years of anticipated funding needs in its reserves (or such reserves as may be advised by the Charity Commission); the five years funding in reserves is an aspiration at the moment. Steps are being taken on the fund-raising front to enhance the level of reserves.

Medically, the Charity is exposed to risk in the following ways:

#### *1. The CARE website*

The CARE website has been reconstructed.

#### *2. CARE Speaker and Social Meetings*

These events bring together members of the Rheumatology Department and patients, with their relatives and friends. Venues selected are used regularly for conferences and present no unusual hazard. Several medical members of the team are present at these events, should medical attention be required.

#### *3. CARE involvement in scientific research and clinical trials*

All scientific research sponsored by CARE is conducted under the ethical and management policies of Cambridge University Hospitals NHS Foundation Trust (CUHNHSFT) (to whom proposals are submitted for peer review). Where CARE staff participate in clinical trials, these are normally conducted on behalf of pharmaceutical companies, or their agents, and therefore subject to the normal regulatory processes. Where CARE sponsors clinical trials directly, these are conducted under the regulations set out by CUHNHSFT, and are subject to ethical review. Insurance against adverse outcomes in any CARE-instigated clinical trial is provided through CUHNHSFT.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## TRUSTEES' REPORT (CONTINUED)

**FOR THE YEAR ENDED 31 MARCH 2021**

---

### **Structure, governance and management**

The Governing document of the Charity is a Declaration of Trust dated 29 January 1990.

The address of the charity is:

Box 194 Unit E6  
Addenbrookes Hospital  
Hills Road  
Cambridge  
Cams  
CB2 0QQ

The Trustees who served during the year and up to the date of signature of the financial statements were:

Professor H Gaston  
Dr N Shenker  
Dr F Hall  
Professor A McCaskie  
Dr D Jadon  
Dr N Jordan

Prospective and newly appointed Trustees are given a detailed understanding of the research work carried out by CARE, so that those who are invited to join are conversant with what is expected of them.

In planning for the coming year, the Trustees agree the framework in which CARE will operate and the day-to-day detail to achieve this is delegated to the staff of CARE. Should the staff wish to change the framework, then an approach is made to the Trustees to seek their authority to make the changes.

The day to day affairs of the charity are run by the Administrator.

The charity's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.

The Trustees' report was approved by the Board of Trustees.

Professor H Gaston  
**Trustee**

19 January 2022

# **CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR**

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

***FOR THE YEAR ENDED 31 MARCH 2021***

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

---

I report to the Trustees on my examination of the financial statements of Cambridge Arthritis Research Endeavour (the Charity) for the year ended 31 March 2021.

#### **Responsibilities and basis of report**

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the Charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### **Independent examiner's statement**

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Mrs J Boatfield ACA  
Ensors Accountants LLP

Victory House  
Vision Park  
Chivers Way  
Histon  
Cambridgeshire  
CB24 9ZR

Dated: 27 January 2022

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2021

|                                       | Notes | Unrestricted<br>funds<br>2021<br>£ | Restricted<br>funds<br>2021<br>£ | Total<br>2021<br>£ | Unrestricted<br>funds<br>2020<br>£ | Restricted<br>funds<br>2020<br>£ | Total<br>2020<br>£ |
|---------------------------------------|-------|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| <b>Income from:</b>                   |       |                                    |                                  |                    |                                    |                                  |                    |
| Donations and legacies                | 3     | 3,245                              | -                                | 3,245              | 2,069                              | -                                | 2,069              |
| Charitable activities                 | 4     | 49,435                             | -                                | 49,435             | 73,609                             | 175,008                          | 248,617            |
| Other income                          | 5     | -                                  | -                                | -                  | 5,800                              | -                                | 5,800              |
| Investment income                     | 6     | 23,837                             | -                                | 23,837             | 24,426                             | -                                | 24,426             |
| <b>Total income</b>                   |       | 76,517                             | -                                | 76,517             | 105,904                            | 175,008                          | 280,912            |
| <b>Expenditure on:</b>                |       |                                    |                                  |                    |                                    |                                  |                    |
| Charitable activities                 | 7     | 210,478                            | 33,554                           | 244,032            | 109,997                            | 182,918                          | 292,915            |
| Net gains/(losses) on investments     | 12    | 138,161                            | -                                | 138,161            | (23,377)                           | -                                | (23,377)           |
| <b>Net movement in funds</b>          |       | 4,200                              | (33,554)                         | (29,354)           | (27,470)                           | (7,910)                          | (35,380)           |
| Fund balances at 1 April 2020         |       | 585,418                            | 57,851                           | 643,269            | 612,888                            | 65,761                           | 678,649            |
| <b>Fund balances at 31 March 2021</b> |       | 589,618                            | 24,297                           | 613,915            | 585,418                            | 57,851                           | 643,269            |

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET

AS AT 31 MARCH 2021

---

|   | Notes | 2021<br>£ | £                | 2020<br>£ | £                |
|---|-------|-----------|------------------|-----------|------------------|
| <b>Fixed assets</b>                                   |       |           |                  |           |                  |
| Tangible assets                                       | 13    |           | 1,572            |           | 2,356            |
| Investments   | 14    |           | 961,148          |           | 799,253          |
|   |       |           | <u>962,720</u>   |           | <u>801,609</u>   |
| <b>Current assets</b>                                 |       |           |                  |           |                  |
| Debtors   | 15    | 73,891    |                  | 50,365    |                  |
| Cash at bank and in hand                              |       | 69,831    |                  | 109,604   |                  |
|   |       |           | <u>143,722</u>   |           | <u>159,969</u>   |
| <b>Creditors: amounts falling due within one year</b> | 16    | (492,527) |                  | (318,309) |                  |
| Net current liabilities                               |       |           | <u>(348,805)</u> |           | <u>(158,340)</u> |
| <b>Total assets less current liabilities</b>          |       |           | <u>613,915</u>   |           | <u>643,269</u>   |
| <b>Income funds</b>                                   |       |           |                  |           |                  |
| Restricted funds                                      | 17    |           | 24,297           |           | 57,851           |
| Unrestricted funds                                    |       |           |                  |           |                  |
| General unrestricted funds                            |       | 589,568   |                  | 585,368   |                  |
| Trustees' subscriptions                               |       | 50        |                  | 50        |                  |
|   |       |           | <u>589,618</u>   |           | <u>585,418</u>   |
|   |       |           | <u>613,915</u>   |           | <u>643,269</u>   |

The financial statements were approved by the Trustees on 19 January 2022

Professor H Gaston  
Trustee

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2021

---

### 1 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 2 Accounting policies

#### Charity information

Cambridge Arthritis Research Endeavour is a Registered Charity governed by a declaration of trust dated 29 January 1980. Its objectives are the relief of persons who are suffering from rheumatoid arthritis and related diseases and to promote and advance medical research and education concerning such disorders provided that the useful results of such research shall be published.

#### 2.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's declaration of trust, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The Charity is a Public Benefit Entity as defined by FRS 102.

The Charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 2.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements subject to the impact that the COVID 19 pandemic might have on the Charity which is unknown at this time.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

---

### 2 Accounting policies

(Continued)

#### 2.3 Charitable funds

Resources received are allocated to restricted funds according to the limitations specified on their use by the donors or other providers. Funds which can be used for general purposes of the Charity are treated as unrestricted. Where income has been received to cover running costs for a project and the costs cannot be directly identified, a transfer is made from unrestricted funds to the relevant restricted fund for this expenditure.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

#### 2.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacy income is recognised when the following conditions have been met: the final estate accounts have been approved, the legacy is capable of measurement and there is no reversionary interest.

Grants received for use in purchasing capital items are included as income within restricted funds and are reduced each year by an amount equivalent to depreciation of those assets.

Revenue grants are included as income on a receivable basis.

Income from drug trials is recognised only when it is certain that payment will be received and can be measured accurately.

#### 2.5 Resources expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

#### 2.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

|                       |                         |
|-----------------------|-------------------------|
| Fixtures and fittings | 15% straight line basis |
|-----------------------|-------------------------|

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

### 2 Accounting policies

(Continued)

#### 2.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

#### 2.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

#### 2.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

#### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

#### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

### 3 Donations and legacies

|                     | Unrestricted<br>funds | Unrestricted<br>funds |
|---------------------|-----------------------|-----------------------|
|                     | 2021                  | 2020                  |
|                     | £                     | £                     |
| Donations and gifts | 3,245                 | 1,569                 |
| Legacies receivable | -                     | 500                   |
|                     | <u>3,245</u>          | <u>2,069</u>          |
|                     | <u><u>3,245</u></u>   | <u><u>2,069</u></u>   |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

### 4 Charitable activities

|                    | 2021<br>£     | 2020<br>£      |
|--------------------|---------------|----------------|
| Grants             | -             | 175,008        |
| Drug trial income  | 49,435        | 73,609         |
|                    | <u>49,435</u> | <u>248,617</u> |
| Analysis by fund   |               |                |
| Unrestricted funds | 49,435        | 73,609         |
| Restricted funds   | -             | 175,008        |
|                    | <u>-</u>      | <u>175,008</u> |

### 5 Other income

|             | Unrestricted<br>funds<br><br>2021<br>£ | Unrestricted<br>funds<br><br>2020<br>£ |
|-------------|--|--|
| Sponsorship | -                                      | 5,800                                  |
|             | <u>-</u>                               | <u>5,800</u>                           |

### 6 Investment income

|               | Unrestricted<br>funds<br><br>2021<br>£ | Unrestricted<br>funds<br><br>2020<br>£ |
|---------------|--|--|
| COIF          | 23,735                                 | 24,196                                 |
| Bank interest | 102                                    | 230                                    |
|               | <u>23,837</u>                          | <u>24,426</u>                          |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

#### 7 Charitable activities

|   | 2021           | 2020           |
|---|----------------|----------------|
|   | £              | £              |
| Staff costs                             | 235,175        | 245,696        |
| Depreciation and impairment             | 784            | 868            |
| Archiving                               | 261            | 265            |
| Conferences and travel                  | 313            | 3,590          |
| Grants                                  | -              | (13,000)       |
| Drug trials                             | (19,151)       | (38,016)       |
| Patient travel                          | 101            | 4,749          |
| Insurance                               | 284            | 278            |
| Stationery and computer supplies        | 1,373          | 1,379          |
| Sundry expenses                         | 7,575          | 4,141          |
| Bank charges                            | 108            | -              |
| Repairs and maintenance                 | -              | 222            |
| Research                                | -              | 63,590         |
|   | <u>226,823</u> | <u>273,762</u> |
| Share of support costs (see note 8)     | 11,518         | 11,197         |
| Share of governance costs (see note 8)  | 5,691          | 7,956          |
|   | <u>244,032</u> | <u>292,915</u> |
| <b>Analysis by fund</b>                 |                |                |
| Unrestricted funds                      | 210,478        | 109,997        |
| Restricted funds                        | 33,554         | 182,918        |
|   | <u>244,032</u> | <u>292,915</u> |
| <b>For the year ended 31 March 2020</b> |                |                |
| Unrestricted funds                      | 109,997        |                |
| Restricted funds                        | 182,918        |                |
|   | <u>292,915</u> |                |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

### 8 Support costs

|  | Support costs | Governance costs | 2021          | Support costs | Governance costs | 2020          |
|--|---------------|------------------|---------------|---------------|------------------|---------------|
|  | £             | £                | £             | £             | £                | £             |
| Staff costs                            | 11,518        | -                | 11,518        | 11,197        | -                | 11,197        |
| Independent examiner's fees            | -             | 1,852            | 1,852         | -             | 4,224            | 4,224         |
| Recharged employment costs             | -             | 3,839            | 3,839         | -             | 3,732            | 3,732         |
|  | <u>11,518</u> | <u>5,691</u>     | <u>17,209</u> | <u>11,197</u> | <u>7,956</u>     | <u>19,153</u> |
| Analysed between Charitable activities | <u>11,518</u> | <u>5,691</u>     | <u>17,209</u> | <u>11,197</u> | <u>7,956</u>     | <u>19,153</u> |

### 9 Grants payable

There were no grants payable in 2021. In 2020 there was a reversal of a prior year accrual in respect of grants payable of £13,000.

### 10 Trustees

During the year, no Trustees received any remuneration (2020 - £nil), benefits in kind (2020 - £nil) or reimbursement of expenses (2020 - £nil) in relation to their role as Trustees. During the year, the charity reimbursed Cambridge University Hospitals NHS Foundation Trust for salary costs in relation to research work carried out by the following Trustees: Dr Jordan £12,864 (2020 - £12,312), Dr Jadon £10,761 (2020 - £10,300) and Dr Hall £12,830 (2020 - £12,280). During the year, no Trustees received expenses. (2020 - £267).

### 11 Employees

There were no employees during the year.

| Employment costs  | 2021           | 2020           |
|---|----------------|----------------|
|   | £              | £              |
| Wages and salaries recharged from Cambridge University Hospitals NHS Foundation Trust | <u>250,532</u> | <u>260,625</u> |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

### 12 Net gains/(losses) on investments

|                            | Unrestricted<br>funds | Unrestricted<br>funds |
|----------------------------|-----------------------|-----------------------|
|                            | 2021                  | 2020                  |
|                            | £                     | £                     |
| Revaluation of investments | 138,161               | (23,377)              |

### 13 Tangible fixed assets

|                                    | Fixtures and fittings<br>£ |
|------------------------------------|----------------------------|
| <b>Cost</b>                        |                            |
| At 1 April 2020                    | 44,736                     |
| At 31 March 2021                   | 44,736                     |
| <b>Depreciation and impairment</b> |                            |
| At 1 April 2020                    | 42,380                     |
| Depreciation charged in the year   | 784                        |
| At 31 March 2021                   | 43,164                     |
| <b>Carrying amount</b>             |                            |
| At 31 March 2021                   | 1,572                      |
| At 31 March 2020                   | 2,356                      |

### 14 Fixed asset investments

|                          | COIF Units | Deposit Fund   | Deposit Fund  | Total   |
|--------------------------|------------|----------------|---------------|---------|
|                          | £          | - Capital<br>£ | - Income<br>£ | £       |
| <b>Cost or valuation</b> |            |                |               |         |
| At 1 April 2020          | 667,412    | 7,023          | 124,818       | 799,253 |
| Valuation changes        | -          | -              | 23,735        | 23,735  |
| Unrealised gain          | 138,160    | -              | -             | 138,160 |
| At 31 March 2021         | 805,572    | 7,023          | 148,553       | 961,148 |
| <b>Carrying amount</b>   |            |                |               |         |
| At 31 March 2021         | 805,572    | 7,023          | 148,553       | 961,148 |
| At 31 March 2020         | 667,412    | 7,023          | 124,818       | 799,253 |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

### 15 Debtors

|   | 2021          | 2020          |
|---|---------------|---------------|
|   | £             | £             |
| <b>Amounts falling due within one year:</b> |               |               |
| Trade debtors                               | 52,983        | 22,233        |
| Other debtors                               | 656           | 656           |
| Prepayments and accrued income              | 20,252        | 27,476        |
|   | <u>73,891</u> | <u>50,365</u> |

### 16 Creditors: amounts falling due within one year

|                                    | 2021           | 2020           |
|------------------------------------|----------------|----------------|
|                                    | £              | £              |
| Other taxation and social security | 2,060          | -              |
| Trade creditors                    | 21,798         | 3,536          |
| Other creditors                    | 402,076        | 217,405        |
| Accruals and deferred income       | 66,593         | 97,368         |
|                                    | <u>492,527</u> | <u>318,309</u> |

### 17 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

|                          | <b>Movement<br/>in funds</b> |                            |                       |                             |
|--------------------------|------------------------------|----------------------------|-----------------------|-----------------------------|
|                          | Incoming<br>resources        | Balance at<br>1 April 2020 | Resources<br>expended | Balance at<br>31 March 2021 |
|                          | £                            | £                          | £                     | £                           |
| ePROMS and ePREMS        | -                            | 48,091                     | -                     | 48,091                      |
| Spondylarthritis Academy | -                            | 9,760                      | (33,554)              | (23,794)                    |
|                          | <u>-</u>                     | <u>57,851</u>              | <u>(33,554)</u>       | <u>24,297</u>               |

# CAMBRIDGE ARTHRITIS RESEARCH ENDEAVOUR

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

#### 18 Analysis of net assets between funds

|  | Unrestricted<br>funds<br>2021<br>£ | Restricted<br>funds<br>2021<br>£ | Total<br>2021<br>£ | Unrestricted<br>funds<br>2020<br>£ | Restricted<br>funds<br>2020<br>£ | Total<br>2020<br>£ |
|--|------------------------------------|----------------------------------|--------------------|------------------------------------|----------------------------------|--------------------|
| Fund balances at 31<br>March 2021 are<br>represented by: |                                    |                                  |                    |                                    |                                  |                    |
| Tangible assets  | 1,572                              | -                                | 1,572              | 2,356                              | -                                | 2,356              |
| Investments  | 961,148                            | -                                | 961,148            | 799,253                            | -                                | 799,253            |
| Current assets/<br>(liabilities)                         | (373,102)                          | 24,297                           | (348,805)          | (216,191)                          | 57,851                           | (158,340)          |
|  | <u>589,618</u>                     | <u>24,297</u>                    | <u>613,915</u>     | <u>585,418</u>                     | <u>57,851</u>                    | <u>643,269</u>     |